Pyridoxine deficiency and toxicity …

Douglas J Lanska MD MS MSPH

Neurotoxicology

Updated 05.01.2024
Released 10.29.2010
Expires For CME 05.01.2027

Pyridoxine deficiency and toxicity

Author: Douglas J Lanska MD MS MSPH

See Contributor Disclosures

Pyridoxine deficiency and toxicity

In This Article

Quick Link

Introduction

Overview

Pyridoxine, or vitamin B6, deficiency and toxicity can involve changes predominantly in hematologic, dermatologic, cardiovascular, gastrointestinal, and neurologic systems. Pyridoxine 5'-phosphate is an essential cofactor in various transamination, decarboxylation, glycogen hydrolysis, and synthesis pathways involving carbohydrate, sphingolipid, amino acid, heme, and neurotransmitter metabolism. Vitamin B6 is required for the production of serotonin and helps to maintain a healthy immune system, protect the heart from cholesterol deposits, and prevent kidney stone formation.

Neurologic disorders reflecting both pyridoxine deficiency and pyridoxine toxicity have been recognized. Both overdose and deficiency may cause peripheral neuropathy. Pyridoxine deficiency causes injury of motor and sensory axons, whereas an overdose of pyridoxine causes a pure sensory neuropathy or neuronopathy with sensory ataxia.

Some drugs, such as isoniazid and enzyme-inducing antiepileptic drugs, interfere with pyridoxine metabolism.

Several hereditary conditions disrupt pyridoxine metabolism, including pyridoxine-dependent epilepsy.

Key points

	• Vitamin B6, also called pyridoxine, is one of eight water-soluble B vitamins. Pyridoxine acts as a coenzyme in the breakdown and utilization of carbohydrates, fats, and proteins.
	• Pyridoxine is essential in numerous biochemical pathways involving the nervous system, red blood cells, the immune system, protein metabolism, homocysteine metabolism, and the production of energy.
	• Pyridoxine is important for maintaining healthy nerve and muscle cells and it aids in the production of DNA and RNA.
	• The recommended daily dose of pyridoxine is 2.0 mg/day for adult men and 1.6 mg/day for adult women. Higher amounts may be recommended for certain conditions.
	• Common sources of pyridoxine include brewer's yeast, carrots, chicken, eggs, fish, meat, peas, spinach, sunflower seeds, whole grains, bread, liver, cereals, spinach, green beans, and bananas.
	• Symptoms of pyridoxine deficiency include neuropathy, confusion, dermatitis, and insomnia.
	• Pyridoxine overdose causes a sensory neuronopathy characterized by poor coordination, numbness, and decreased sensation to touch, temperature, and vibration.
	• Several hereditary conditions disrupt pyridoxine metabolism, including pyridoxine-dependent epilepsy and pyridoxamine 5'-phosphate oxidase deficiency (PNPOD).

Historical note and terminology

Pyridoxine (vitamin B6) was discovered in 1934 by Hungarian-born American biochemist, nutritionist, and pediatrician Paul György (1893-1976) (206). At that time vitamin B6 was recognized as a new component of the vitamin B complex of water-soluble vitamins that cured a nutritional skin disorder of rats called “rat acrodynia.” Young rats kept on a semisynthetic diet with added vitamin B1 (thiamine) and B2 (riboflavin) developed severe skin lesions with edema, erythema, and scaliness affecting their paws, snout, nose, and ears. Using rat acrodynia as a bioassay, György and his colleagues successfully isolated and characterized vitamin B6. Vitamin B6 was subsequently isolated and crystallized by Samuel Lepkovsky (1899-1984) in 1938 (140) and first synthesized (by two different research groups) in 1939 (93; 129).

Between 1951 and 1954, hyperirritability and convulsive seizures developed in 54 infants fed formula that was later shown to be deficient in pyridoxine (53). This was recognized by pediatrician David B Coursin of St. Joseph's Hospital in Lancaster, Pennsylvania.

Pyridoxine-dependent epilepsy was first described in 1954 by pediatrician Andrew D Hunt Jr and colleagues at the Children's Hospital of Philadelphia and the Department of Pediatrics at the University of Pennsylvania School of Medicine, Philadelphia (100).

Sensory neuronopathy from pyridoxine abuse was first recognized in the 1980s, initially by neurologist Herbert H Schaumburg and colleagues at Albert Einstein College of Medicine in 1983 (218).

Clinical manifestations

Presentation and course

	• Pyridoxine deficiency can manifest with neurologic, dermatologic, cardiologic, gastrointestinal, and hematologic symptoms.
	• Central nervous system symptoms of pyridoxine deficiency include depression, anxiety, irritability, confusion, generalized seizures, and white matter lesions. In addition, some patients have generalized weakness and dizziness.
	• Pyridoxine deficiency causes a mixed distal symmetric polyneuropathy presenting as bilateral, distal limb numbness or pain and rarely distal limb weakness; examination is consistent with a large-fiber neuropathy.
	• Adults with neuropathy due to pyridoxine deficiency may have reduced vibration sensation and proprioception with preserved pain and temperature sensation, as well as a sensory ataxia from large fiber involvement.
	• Older patients with pyridoxine deficiency may have confusion, dementia, disorientation, rigidity, and primitive reflexes, whereas neurologic signs in neonates and young infants include hypotonia; irritability; restlessness; focal, bilateral motor, or myoclonic seizures; and infantile spasms.
	• Pyridoxine-dependent epilepsy usually manifests with a combination of seizure types in the first hours of life, which are unresponsive to standard anticonvulsants, but respond to immediate administration of pyridoxine hydrochloride.
	• Vitamin B6 is usually safe, at doses up to 200 mg per day in adults. When taken at higher doses or over a long period of time, vitamin B6 can produce a range of nonspecific systemic symptoms, including nausea, vomiting, diarrhea, tachypnea, and rash. Patients may develop a neuropathy with distal sensory loss and paresthesias.
	• Some patients with pyridoxine toxicity, particularly with mega doses of pyridoxine (ie, greater than 2 g/day), may develop a sensory neuronopathy with severe sensory loss throughout the body; the resulting loss of proprioception can produce a dramatic sensory ataxia.

Pyridoxine deficiency can manifest with neurologic, dermatologic, cardiologic, gastrointestinal, and hematologic symptoms. Central nervous system symptoms include depression, anxiety, irritability, confusion, generalized seizures, and white matter lesions. In addition, some patients have generalized weakness and dizziness (40). Dermatologic symptoms include erythematous itching, burning, blisters, vesicles, hyperpigmentation, and thickening of skin, similar to that seen with vitamin B2 (riboflavin) and vitamin B3 (niacin) deficiencies. Gastrointestinal symptoms include nausea, diarrhea, abdominal discomfort, and pain. Hematologic manifestations can include anemia, which most often presents with fatigue. Low-serum pyridoxal 5'-phosphate concentration has been associated with indicators of poor nutritional status and may be related to increased hemolysis in children with sickle cell disease (177).

Pyridoxine deficiency causes a mixed distal symmetric polyneuropathy presenting as bilateral, distal limb numbness or pain and rarely distal limb weakness. Examination is consistent with a large-fiber neuropathy.

Adults with neuropathy may have reduced vibration sensation and proprioception with preserved pain and temperature sensation, as well as a sensory ataxia from large fiber involvement. In addition, older patients may have confusion, dementia, disorientation, rigidity, and primitive reflexes. In neonates and young infants, neurologic signs include hypotonia; irritability; restlessness; focal, bilateral motor, or myoclonic seizures; and infantile spasms. Additional physical examination findings in pyridoxine deficiency may include glossitis, cheilosis, and seborrheic dermatitis. Multiple cooccurring nutritional deficiencies may act synergistically with pyridoxine deficiency to produce a devastating neuropathy.

Pyridoxine-dependent epilepsy usually manifests with a combination of seizure types (including myoclonic seizures, infantile spasms, and status epilepticus) in the first hours of life, which are unresponsive to standard anticonvulsants, but respond to immediate administration of pyridoxine hydrochloride (193; 239). Additional manifestations may include excessive irritability, tremulousness, and poor psychomotor development. Interruption of daily pyridoxine supplementation results in recurrence of seizures. Some patients show developmental delay. Rare later-onset cases have also been reported, with progressively worsening, treatment-refractory seizures beginning at 14 months of age (69).

Several studies have noted a high frequency of pyridoxine deficiency in patients with established (benzodiazepine-resistant) status epilepticus. A retrospective cohort study of 293 hospitalized patients with established status epilepticus found that these patients had a significantly higher prevalence of marginal and deficient pyridoxal phosphate (PLP) levels (90 and 80%, respectively) than patients in each of the three control groups (ie, intensive care unit patients without status epilepticus, non–intensive care unit inpatients without status epilepticus, and outpatients with or without a history of epilepsy) (208). This significantly higher prevalence persisted after correcting for critical illness severity and timing of PLP level collection.

In a prospective case series of 30 adults with epilepsy categorized by level of control (based on the crude metric of a seizure within the prior 3-month period), "poorly controlled" individuals had significantly lower serum pyridoxine levels (196).

Toxicity. Vitamin B6 is usually safe, at doses up to 200 mg per day in adults, although a case of pyridoxine toxicity-related peripheral neuropathy has been reported with daily multivitamin use (6 mg of pyridoxine daily) (184). When taken at higher doses or over a long period of time, vitamin B6 can produce a range of nonspecific systemic symptoms, including nausea, vomiting, diarrhea, tachypnea, and rash. Patients may develop a neuropathy with distal sensory loss and paresthesias (174; 184). Muscle weakness and rhabdomyolysis have been described in a few patients, and Achilles reflexes are typically lost (11). An infant with homocystinuria due to a deficiency of cystathionine beta-synthase was given a pyridoxine challenge with high-dose pyridoxine to determine responsiveness but developed respiratory failure and rhabdomyolysis consistent with pyridoxine toxicity, highlighting the need for weight-based dosing and duration recommendations for pyridoxine challenge in neonates (11).

Some patients with pyridoxine toxicity, particularly with mega doses of pyridoxine (ie, greater than 2 g/day), may develop a sensory neuronopathy with severe sensory loss throughout the body (235; 218; 186; 56; 07; 57; 06; 157; 134; 62; 77; 37; 131). Loss of proprioception can produce a dramatic sensory ataxia.

Prognosis and complications

Pyridoxine has the highest rate of adverse outcomes per toxic exposure for any vitamin, although no deaths have been reported.

Both pyridoxine deficiency and excess may cause peripheral neuropathy. The neuropathy associated with pyridoxine deficiency may improve with pyridoxine replacement or when responsible medications that interfere with pyridoxine metabolism (eg, isoniazid) are stopped, but the neuropathy may not completely resolve.

Despite medical management, patients with pyridoxine-dependent seizures may have developmental delay, particularly in expressive language.

Injecting pyridoxine into an infant or neonate can cause a precipitous decrease in blood pressure (85).

Deficiency of pyridoxine can cause hyperoxalemia and hyperoxaluria in patients with chronic kidney disease, potentially compounding kidney dysfunction (175).

Inadequate B6 levels have been linked to an increased risk of age-related chronic diseases (eg, cardiovascular disease and cancer), sarcopenia (ie, age-related loss of muscle mass and strength), frailty (ie, a decline in physiological resilience and increased vulnerability associated with aging), and all-cause mortality in adults (118). Proposed mechanisms involve P2X7 receptor-mediated NLRP3 inflammasome signaling, AMPK signaling, PD-L1 signaling, and satellite cell-mediated myogenesis (118). In addition, B6 deficiency–associated modulation of PLP-dependent enzymes impairs energy utilization and affects imidazole peptide production and hydrogen sulfide production, as well as the kynurenine pathway, which can all impact skeletal muscle health.

Pyridoxine blocks lactation and inhibits the secretion of breast milk in nursing mothers by suppressing the normally elevated prolactin hormone levels encountered during the puerperium (87).

With neuropathy associated with pyridoxine toxicity, complete recovery may occur in patients with a mild neuropathy who have been taking only low doses of the vitamin (117). The sensory neuronopathy caused by pyridoxine overdose shows little improvement. Sensory neuronopathy from pyridoxine overdose can begin approximately 1 month to 3 years following supplementation. Although this usually occurs at very high supplementation doses, complications have been reported with doses as low as 50 mg/d (220).

Biological basis

	• Pyridoxine is obtained from two exogenous sources: (1) a dietary source, which is absorbed in the small intestine; and (2) a bacterial source, where the vitamin is synthesized in significant quantities by the normal microflora of the large intestine.
	• Pyridoxine is absorbed by a specific and regulatable carrier-mediated process for pyridoxine uptake by mammalian colonocytes.
	• Pyridoxine is utilized by the liver to synthesize pyridoxal 5'-phosphate, which functions as a coenzyme in transamination and decarboxylation reactions involved in amino acid and protein metabolism, and also as a coenzyme in the biosynthesis of heme, niacin, and serotonin.
	• Pyridoxal deficiency can contribute to a metabolic deficiency of niacin and the clinical disorder pellagra.
	• Clinically manifest dietary pyridoxine deficiency is rare, though medical conditions or procedures can increase the risk for pyridoxine deficiency, including celiac disease, renal dialysis, total parenteral nutrition, severe malnutrition, rheumatoid arthritis, alcoholism, alcoholic liver disease, subacute hepatic necrosis, and sickle cell disease.
	•Drugs can cause clinical manifestations of pyridoxine deficiency if they either react with pyridoxal phosphate or affect the metabolism of B6 vitamers.
	• Inherited disorders of pyridoxine metabolism include inborn errors that lead to accumulation of small molecules that react with pyridoxal phosphate and inactivate it, inborn errors that affect the pathways of pyridoxine metabolism, and inborn errors that affect specific pyridoxal phosphate-dependent enzymes.
	• Sensory neuronopathy (and less commonly a sensorimotor neuropathy) may develop in patients who consumed high doses of pyridoxine; pyridoxine given in large doses selectively destroys large-diameter peripheral sensory nerve fibers, leaving motor fibers intact.

Etiology and pathogenesis

Biochemistry and metabolism. Vitamin B6 or pyridoxine is a complex of six vitamers: pyridoxal, pyridoxine (pyridoxol), pyridoxamine, and their respective 5'-phosphate esters, pyridoxal 5'-phosphate, pyridoxine 5'-phosphate, and pyridoxamine 5'-phospate. Pyridoxal 5'-phosphate is the active coenzyme form and has the most importance in human metabolism.

Pyridoxal

(Contributed by Douglas J Lanska MD MS MSPH. Courtesy of Wikipedia. Public domain.)
Pyridoxine (pyridoxol)

(Contributed by Douglas J Lanska MD MS MSPH. Courtesy of Wikipedia. Public domain.)
Pyridoxamine

(Contributed by Douglas J Lanska MD MS MSPH. Courtesy of Wikipedia. Public domain.)
Pyridoxal 5'-phosphate

Pyridoxal 5'-phosphate, the active coenzyme form of vitamin B6 (pyridoxine). (Contributed by Douglas J Lanska MD MS MSPH. Courtesy of Wikipedia. Public domain.)

Pyridoxine is obtained from two exogenous sources: (1) a dietary source, which is absorbed in the small intestine; and (2) a bacterial source, where the vitamin is synthesized in significant quantities by the normal microflora of the large intestine (211). Pyridoxine is absorbed by a specific and regulatable carrier-mediated process for pyridoxine uptake by mammalian colonocytes (211).

Pyridoxine is utilized by the liver to synthesize pyridoxal 5'-phosphate. Pyridoxal 5'-phosphate functions as a coenzyme in transamination and decarboxylation reactions involved in amino acid and protein metabolism. Pyridoxal 5'-phosphate also acts as a coenzyme in the biosynthesis of heme and multiple neurotransmitters.

Pyridoxal 5'-phosphate is a coenzyme that is necessary for methionine metabolism. With pyridoxine deficiency-induced methionine deficiency, S-adenosylmethionine accumulates, resulting in the inhibition of sphingolipid and myelin synthesis.

Homocysteine metabolism is dependent on pyridoxine, and high homocysteine levels can result from pyridoxine deficiency. In combination with folic acid and vitamin B12, vitamin B6 lowers levels of homocysteine, an amino acid linked to heart disease and stroke and possibly to other diseases, such as osteoporosis and Alzheimer disease.

Tryptophan is a precursor to several neurotransmitters and is required for niacin production. Pyridoxine is a cofactor in the transformation of tryptophan to niacin (143). In the presence of pyridoxal phosphate deficiency, tryptophan is diverted instead to xanthurenic acid, which is excreted in the urine. Consequently, pyridoxal deficiency can contribute to a metabolic deficiency of niacin and the clinical disorder pellagra (154; 50; 102).

The neurotransmitters dopamine, serotonin, epinephrine, norepinephrine, glycine, glutamate, and GABA also require pyridoxal 5'-phosphate for their production. Pyridoxal phosphate is a cofactor for the enzyme aromatic amino acid decarboxylase, which is required for the production of monoamine neurotransmitters (ie, serotonin, dopamine, norepinephrine, and epinephrine). Aromatic amino acid decarboxylase is responsible for converting the precursors 5-hydroxytryptophan (5-HTP) into serotonin and levodopa (L-dopa) into dopamine (which is subsequently converted by other enzymes into norepinephrine and epinephrine). Pyridoxal phosphate is also a cofactor for the enzyme glutamic acid decarboxylase, which is required for the formation of gamma aminobutyric acid (GABA) from glutamic acid. Therefore, pyridoxal phosphate deficiency alters the balance between inhibitory GABAergic and excitatory glutaminergic neurotransmission, which can lead to seizures.

After absorption, pyridoxine, pyridoxamine, and pyridoxal are transported into hepatic cells by facilitated diffusion. Pyridoxal kinase phosphorylates pyridoxine and pyridoxamine, after which they are converted to pyridoxal 5'-phosphate by a flavin-dependent enzyme. Pyridoxal 5'-phosphate either remains in the hepatocyte, where it is bound to an apoenzyme, or it is released into the serum, where it is tightly bound to lysine residues of proteins, mostly albumin. Free pyridoxal is degraded by alkaline phosphatase, hepatic and renal aldehyde oxidases, and pyridoxal dehydrogenase. Excessive intake of pyridoxine may saturate either of these enzyme systems, with a resultant accumulation of (inactive) pyridoxine, which occupies binding sites on the appropriate apoenzymes and, thus, acts as a competitive inhibitor for pyridoxal phosphate. In essence, an excess or overdose of pyridoxine leads to a deficiency of pyridoxal phosphate.

The vitamin B6 salvage pathway. The different vitamers are converted into pyridoxal 5′-phosphate (PLP) through the “B6 salvage pathway,” which involves the enzymes pyridoxal kinase (PDXK), pyridoxine 5′-phosphate oxidase (PNPO), and pyridoxal phosphatase (PDXP) (90). To enter a cell, phosphorylated vitamers are hydrolyzed by tissue-nonspecific alkaline phosphatase (ALPL). Once inside the cell, PDXK phosphorylates the different vitamers, yielding pyridoxine-5’-phosphate (PNP), pyridoxamine 5’-phosphate (PMP), and pyridoxal 5′-phosphate (PLP). PMP and PNP are converted into PLP by pyridoxine 5′-phosphate oxidase (PNPO). Transaminases may also interconvert PMP and PLP. Pyridoxal phosphatase (PDXP), along with other phosphatases, hydrolyze phosphorylated vitamin B6 vitamers, enabling them to exit the cell. Pyridoxal is eliminated from the body following its conversion to 4-pyridoxic acid (4-PA), which is catalyzed by aldehyde oxidase (AOX1).

Entry of B6 vitaminers into a cell

To enter a cell, phosphorylated vitamers are hydrolyzed by tissue-nonspecific alkaline phosphatase (ALPL). Once inside the cell, pyridoxal kinase phosphorylates the different vitamers, yielding pyridoxine-5’-phosphate (PNP), py...
Conversion of vitamin B6 vitamers into the active form of vitamin B6

Only dephosphorylated B6 vitamers can enter (or exit) the cell. Once inside the cell, pyridoxal kinase (PDXK) phosphorylates the different vitamers, yielding pyridoxine-5’-phosphate (PNP) from pyridoxine (PN), pyridoxamine 5’-p...
Elimination of vitamin B6

Pyridoxal (PL) is eliminated from the body following its conversion to 4-pyridoxic acid (4-PA), catalyzed by aldehyde oxidase (AOX1). Legend: 4-PA, 4-pyridoxic acid; AOX1, aldehyde oxidase; pyridoxal, PL. (Contributed by Dr. Do...

Pyridoxine deficiency. At the recommended dietary allowance for most Americans, substantial proportions of some population subgroups do not meet accepted criteria for adequate vitamin B6 status (169; 170). Nevertheless, clinically manifest dietary pyridoxine deficiency is rare, though medical conditions or procedures can increase the risk for pyridoxine deficiency. Such conditions include celiac disease (which causes malabsorption of B6 vitamers), renal dialysis (which increases losses of B6 vitamers from the circulation), total parenteral nutrition (which may fail to include sufficient B6 vitamers in the infusion), as well as severe malnutrition, rheumatoid arthritis, alcoholism, alcoholic liver disease (including decompensated cirrhosis), subacute hepatic necrosis, and sickle cell disease (146; 257; 60; 168; 136; 147; 160; 161; 40; 41; 48; 91; 232). Alcoholism-induced pyridoxine deficiency may exacerbate seizures and prove intractable to anticonvulsants until pyridoxine has been repleted (232). Pyridoxine metabolism in sickle cell disease may be disturbed as a function of riboflavin status (02) and may vary across different tissues (176). Although pyridoxine deficiency can develop in persons of any age, elderly persons are at increased risk (169; 270).

At one institution, among patients with documented pyridoxine levels, pyridoxine deficiency was seen in 94% of adult patients with status epilepticus compared to 39% of outpatients with epilepsy, suggesting a causal relationship between pyridoxine levels and status epilepticus (61). To validate this finding, a prospective study is needed in which all cases of status epilepticus have pyridoxine levels determined.

Medication- or toxin-induced pyridoxine deficiency. Drugs can cause clinical manifestations of pyridoxine deficiency if they either react with pyridoxal phosphate or affect the metabolism of B6 vitamers (137; 48). For example, medication-induced pyridoxine deficiency may be caused by antituberulosis drugs isoniazid (INH or isonicotinic hydrazide) and pyrazinamide and by enzyme-inducing antiepileptic drugs (167), carbidopa (202; 268; 274), hydralazine (197), cycloserine (152), carboplatin (243; 217), and D-penicillamine. Different studies have reported divergent results in terms of any effects of oral contraceptives on pyridoxine levels (139; 163; 205; 14; 30; 30; 263; 51).

Pyridoxine has been used as an antidote in acute intoxications, including Gyromitra mushroom or false morel (monomethylhydrazine) poisoning (142; 138). In the stomach, gyromitrin is metabolized to monomethylhydrazine, which is the active metabolite responsible for inhibiting many enzymatic processes, particularly by the inhibition of pyridoxine.

Isoniazid. Patients treated with isoniazid for tuberculosis (or for conversion of a tuberculin skin test)—an agent that inhibits pyridoxine phosphorylation—may develop peripheral neuropathy due to pyridoxine deficiency if they do not take supplemental pyridoxine (207; Badrinath and John 2024). Isoniazid serves as a prodrug that undergoes metabolic activation by a mycobacterial enzyme and then interferes with the mycobacterial synthesis of mycolic acids (very long-chain lipids that are important components of mycobacterial cell walls); consequently, isoniazid is a potent tuberculostatic agent. Isoniazid was first made available in 1952, but soon there were numerous reports of neurotoxicity related to the use of isoniazid (23; 75), including particularly peripheral neuropathy, which may be painful (110; 144; 24; 25; 13; 99; 148; 255) and seizures (82). Peripheral neuropathy is significantly higher among slow than among rapid inactivators of isoniazid (254). Other studies documented other manifestations of isoniazid neurotoxicity, including optic neuropathy (119; 116; 115; 76; 108; 84; 125; 124; 181; 132), confusion (200), encephalopathy (01), toxic psychosis (04), obtundation and coma (82; 32; 47), and a cerebellar syndrome (27).

Peripheral neuropathy was recognized as a particularly frequent side effect of isoniazid therapy, affecting approximately 40% of patients in early studies (24; 25). Similarities of isoniazid-related neuropathy to that produced by the pyridoxine antagonist, desoxypyridoxine, led Biehl and colleagues to investigate the effect of isoniazid on pyridoxine metabolism in the early 1950s. They found a dose-effect relationship between dose of isoniazid administered and the frequency of peripheral neuropathy in patients and an inverse relationship between dose and time to development of toxic manifestations. Furthermore, they found that concurrent administration of pyridoxine could prevent the development of peripheral neuropathy even with large doses of isoniazid.

Further studies demonstrated that isoniazid interferes with the metabolism of pyridoxine (vitamin B6) (233). The principle biologically active form of pyridoxine (vitamin B6) is pyridoxal 5'-phosphate, which can form a Schiff base (ie, a compound with a functional group that contains a carbon-nitrogen double bond with the nitrogen atom connected to an aryl or alkyl group) with various drugs, including isoniazid, hydralazine, cycloserine, and penicillamine. In the case of isoniazid specifically, an isonicotyl hydrazine of pyridoxal is formed and excreted. Thus, formation of such complexes reduces the availability of the biologically active form of vitamin B6. Hence, all of these drugs are associated with vitamin B6-responsive neurotoxicity (but note that coadministration of isoniazid and pyridoxine does not interfere with the antituberculous activity of isoniazid).

Isoniazid can also differentially affect decarboxylation of L-Dopa and 5HTP and the formation of serotonin seems to be much more sensitive to isoniazid-induced pyridoxal phosphate deficiency than the formation of dopamine. Consequently, serotonin-deficiency phenomena (eg, behavioral disorders, sleep problems, etc.) but not dopamine-deficiency phenomena (eg, parkinsonism) have been reported with isoniazid toxicity (31).

Isoniazid toxicity (mediated by impaired pyridoxine metabolism) has a variety of neurologic consequences. Specifically, acute isoniazid toxicity produces seizures (82) and encephalopathy, obtundation, and coma (82) whereas chronic toxicity may be associated with peripheral neuropathy, optic neuropathy, and rarely with pellagra (154; 34; 50; 102) or coma (32; 213). Other reported neurologic manifestations include hyperkinesias and ataxia. Other nonneurologic manifestations include liver dysfunction (toxic hepatitis) and a sideroblastic anemia (199; 155; 222; 63).

In adults, acute ingestion of as little as 1.5 g of isoniazid can produce toxicity. Doses larger than 30 mg/kg often produce seizures whereas doses of 80 mg/kg or more can be rapidly fatal (204). The first signs and symptoms of isoniazid toxicity usually appear 30 minutes to 2 hours after ingestion (204). Symptoms and signs of isoniazid overdose include nausea, vomiting, ataxia, confusion, irritability, agitation, sleep disturbances, lethargy, coma, generalized tonic-clonic seizures, and severe metabolic acidosis (with a high anion gap) (10). Pyridoxine administered intravenously is the only effective antidote and can effectively treat both the seizures and the alternations in arousal and mentation. The seizures are otherwise poorly responsive to standard anticonvulsant therapy. Although small doses of pyridoxine (or moderate to large doses of parenteral benzodiazepines) may be sufficient to stop the seizures associated with isoniazid overdose or toxicity, large doses of pyridoxine may be required to completely reverse the full spectrum of signs and symptoms, including the altered level of arousal. In any case, it is generally recommended to combine the use of pyridoxine and benzodiazepines (eg, diazepam) because in animal models the combination has a synergistic effect in terminating seizures associated with pyridoxine deficiency states (226; 185; 166). The initial dose of pyridoxine should be equal to the estimated amount of isoniazid ingested (226; 261; 273; 204; 247; 251; 166). Unfortunately, intravenous pyridoxine is typically stocked in limited quantities in hospitals, and many providers are unfamiliar with isoniazid toxicity, which can confound effective treatment of cases of isoniazid overdose or toxicity (221; 216; 171). Hemodialysis is an important adjunct to pyridoxine therapy in those with persistent coma or refractory seizures or in case of renal failure (225; 183; 36; 247; 245).

Children (and less commonly adults) can present with status epilepticus and the associated metabolic acidosis and coma can be mistakenly attributed solely to the prolonged seizures (162; 33; 228; 10; 231; 44; 150; 35; 166). Therefore, isoniazid toxicity should be considered in patients with refractory seizures (78), obtundation or coma (32; 262; 47; 246), and metabolic acidosis (10).

Risk factors for unintentional overdose or toxicity from isoniazid include children of patients taking isoniazid (including newborn infants of mothers taking isoniazid), uremia/dialysis, higher doses of isoniazid, and lack of concomitant pyridoxine prophylaxis (156; 187; 15; 39; 166). Patients on dialysis are particularly sensitive to isoniazid neurotoxicity in part because pyridoxal phosphate is rapidly cleared by dialysis, which compounds the toxicity of isoniazid (228). Consequently, hemodialysis patients requiring isoniazid therapy should receive supplemental pyridoxine at a dose of 100 mg/day (rather than the usual amount of 50 mg/day) (228). Overdose in adults can occur as a suicide attempt or when individuals attempt to make up missed doses at one time (227; 26; 82; 180; 244; 242; 120). In children, acute isoniazid toxicity should be suspected in those presenting with new-onset seizures (with or without a fever), particularly in those with known access to isoniazid (221).

Peripheral neuropathy is generally a rare complication of isoniazid when small doses are used. However, in malnourished individuals, the risk is apparently significantly greater (64). Neuropathy develops particularly in slow inactivators of isoniazid and can be prevented by concomitant administration of pyridoxine 6 mg daily (277; 128). Although risk can be minimized with concomitant pyridoxine administration, this is often not feasible for use in poorly developed countries; in such situations, vitamin B complex is often more practical (64). In addition, pyridoxine itself can cause a sensory peripheral neuropathy (179), though usually with high doses, and generally reversible with discontinuation of pyridoxine supplementation (although in severe cases there may be marked loss of large myelinated fibers) (215).

Optic neuropathy is a relatively rare side effect of isoniazid but when it occurs, it can be ameliorated by withdrawal of isoniazid and treatment with pyridoxine and possibly also corticosteroids (119; 116; 115; 76; 108; 84; 125; 124; 181; 132).

Isoniazid may precipitate pellagra (154; 50; 102), sometimes even despite pyridoxine supplementation (59). Withdrawal of isoniazid and supplementation with niacin can result in rapid clinical improvement. Isoniazid is metabolized by arylamine N-acetyltransferase and individuals with a less active form of this enzyme do not break down isoniazid efficiently and are more susceptible to pellagra.

Antiepileptic drugs. Treatment with enzyme-inducing antiepileptic drugs (antiepileptic drugs such as phenytoin or carbamazepine) compared to noninducing antiepileptic drugs (eg, levetiracetam, lamotrigine, or topiramate) commonly causes pyridoxine deficiency, which may be severe (167). This may contribute to the polyneuropathy sometimes attributed to older antiepileptic drugs.

Carbidopa. Levodopa is decarboxylated to dopamine by DOPA decarboxylase, which requires PLP as a cofactor. To inhibit peripheral metabolism of L-DOPA (outside the brain) and the associated adverse symptoms (eg, nausea/vomiting, dizziness, headache, and somnolence), and to ensure a greater proportion of the prodrug is delivered to the brain, L-DOPA is usually combined with carbidopa, which inhibits aromatic-L-amino-acid decarboxylase (or "DOPA decarboxylase"). Carbidopa is a hydrazine derivative that binds covalently to PLP, blocking L-DOPA decarboxylation. Because the carbidopa-PLP bond is irreversible, chronic treatment with carbidopa produces systemic vitamin B6 depletion, particularly in subjects treated with high doses of carbidopa (202; 268). Carbidopa-induced pyridoxine deficiency can be symptomatic, particularly with anemia (274), and probably with neuropathy, but also (albeit uncommonly) with refractory seizures (268).

A decrease in PLP leads to a decrease in the irreversible conversion (decarboxylation) of L-glutamic acid to the inhibitory neurotransmitter GABA by the PLP-dependent enzyme glutamic acid decarboxylase (GAD). In mammals, GAD exists in two isoforms with molecular weights of 67 and 65 kDa (GAD67 and GAD65), which are encoded by different genes on different chromosomes (GAD1 on chromosome 2 and GAD2 on chromosome 10). GAD67 and GAD65 are both expressed in the brain where GABA is used as a neurotransmitter. The GAD active site involves a Schiff base linkage between PLP and Lys405.

Effects of decrease in pyridoxal phosphate (schematic)

Schematic diagram showing how a decrease in vitamin B6 (pyridoxine, or its activated form, pyridoxal 5'-phosphate) leads to a decrease in the conversion of the excitatory neurotransmitter glutamic acid to the inhibitory neurotr...
X-ray crystal structure of the 67kDa isoform of glutamic acid decarboxylase (GAD67)

(Source: Image by Buckle AM, Fenalti G, Law RH, Whisstock JC. [2007]. https://www.rcsb.org/structure/2OKJ. Public domain.)
GAD active site with Schiff base linkage between PLP and Lys405

GAD67 active site containing PLP-glutamate complex (shown in green), with Schiff base linkage at Lys405. Side chain residues shown in red. (Source: Image by "OceanicTrees" via Wikipedia. Creative Commons Attribution-Share Alike...

Carbidopa-induced pyridoxine deficiency may also help explain the high frequency of neuropathy in patients with Parkinson disease (203; 72), especially in patients treated with levodopa/carbidopa intestinal gel infusion (111; 159; 189).

In a cross-sectional retrospective study of vitamin B6 plasma levels in 24 patients with Parkinson disease treated with L-DOPA/carbidopa for 3 or more years, all six patients treated with intraduodenal L-DOPA/carbidopa and 13 of 18 patients orally treated with L-DOPA/carbidopa had low plasma levels of vitamin B6; two thirds of the intraduodenal group had pyridoxine levels below the limit of quantification (202). Moreover, eight (42%) of the 19 patients with low vitamin B6 levels had symptoms of hypovitaminosis B6 (anemia and stomatitis/glossitis).

Carboplatin. Carboplatin forms complexes with pyridoxine (243), which can interfere with the action of carboplatin as an antitumor agent and can also produce symptomatic pyridoxine deficiency with neuropathy and depression (217).

Scheme of complexes of the Pt(NH3)2(OH)+ moiety of carboplatin with the B vitamins

Scheme of complexes of the Pt(NH3)2(OH)+ moiety of carboplatin with the B vitamins, including vitamin B6 (pyridoxine, or its active form pyridoxal 5'-phosphate). The only vitamin with a positive charge is thiamine (vitamin B1)....
Absorbance spectrum of a vitamin B6 and carboplatin mixture in an incubation buffer over time

The physico-chemical characterization of the interaction of these chemicals was performed using UV-vis (ultraviolet-visible) spectroscopic techniques in the wavelength range from 190 to 500 nm. UV-vis spectrophotometers use a l...

Inherited disorders of pyridoxine metabolism. There are several different genetic mechanisms that lead to an increased requirement for pyridoxine or pyridoxal phosphate. These include inborn errors that lead to accumulation of small molecules that react with pyridoxal phosphate and inactivate it, inborn errors affecting the pathways of pyridoxine metabolism, and inborn errors affecting specific pyridoxal phosphate-dependent enzymes.

Inherited pyridoxine-responsive (or pyridoxal 5'-phosphate-responsive) conditions include the following (95):

(1) Autosomal-recessive pyridoxine-dependent neonatal epilepsy (OMIM #266100) is caused by deficiency or dysfunction of the enzyme antiquitin or ATQ1 (also known as α-amino-adipic semialdehyde dehydrogenase; and aldehyde dehydrogenase 7 family, member A1 or ALDH7A1), a key enzyme in lysine oxidation (164; 237; 55; 114).

Hypsarrhythmia during cluster seizures in a patient with pyridoxine-dependent epilepsy (EEG)

EEG showed hypsarrhythmia during frequent cluster seizures in a patient with pyridoxine-dependent epilepsy caused by an ALDH7A1 mutation. The EEG was obtained at the age of 2 years before pyridoxine was used. (Source: ...
Burst suppression in a patient with pyridoxine-dependent epilepsy (EEG)

EEG showed burst suppression in a patient with pyridoxine-dependent epilepsy caused by an ALDH7A1 mutation. The EEG was obtained at the age of 1 month before pyridoxine was used. (Source: Jiao X, Gong P, Niu Y, Zhang Y...

Despite adequate seizure control by early high-dose pyridoxine treatment, most patients (at least 75%) with pyridoxine-dependent neonatal epilepsy due to deficiency of α-aminoadipic semialdehyde dehydrogenase (ALDH7A1) have developmental delay and intellectual disability (55; 272). Neuroimaging shows progressive severe cerebral atrophy, with a frontotemporal predominance.

Bilateral brain atrophy in a child with pyridoxine-dependent epilepsy

Bilateral brain atrophy in 3-year-old patient with pyridoxine-dependent epilepsy caused by an ALDH7A1 mutation. The patient had severe intellectual disability and global developmental delay. Seizure types without pyrid...

ALDH7A1-deficient mice with seizure control exhibit altered adult hippocampal neurogenesis and impaired cognitive functions (272). ALDH7A1 deficiency leads to the accumulation of toxic lysine catabolism intermediates (eg, alpha-aminoadipic-delta-semialdehyde and its cyclic form, delta-1-piperideine-6-carboxylate), which impair de novo pyrimidine biosynthesis and inhibit neural stem cell proliferation and differentiation (272). In ALDH7A1-deficient adult mice, supplementation of pyrimidines rescues abnormal neurogenesis and cognitive impairment.

To improve outcome, a lysine-restricted diet and competitive inhibition of lysine transport using pharmacologic doses of arginine are recommended as an adjunct therapy (55).

(2) Pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency (OMIM #610090) (70; 79; 81).

(3) Pyridoxal phosphate-binding protein deficiency due to biallelic mutations in the PLPBP gene (OMIM *604436) on chromosome 8p11.23

(4) Some X-linked and autosomal-recessive forms of pyridoxine-responsive sideroblastic anemia (OMIM #300751 and 206000)

(5) Some milder autosomal-recessive cases of pyridoxine-responsive homocystinuria due to cystathionine beta-synthase deficiency (OMIM #236200)

(6) Autosomal recessive infantile hypophosphatasia (HPP; OMIM #241500) due to homozygous, compound heterozygous, or heterozygous loss-of-function mutations in the ALPL gene (OMIM #171760) on chromosome 1p36.12, resulting in deficient activity of serum tissue nonspecific alkaline phosphatase (TNSALP) (224). In all types of hypophosphatasia, abnormal mineralization of bone leads to rickets/osteomalacia and pathological fractures (92). Low TNSALP isoenzyme activity results in extracellular accumulation of its substrates, including pyridoxal 5′-phosphate (PLP) and inorganic pyrophosphate (PPi), a potent inhibitor of mineralization (122); however, concomitant B6 deficiency can negate the utility of elevated PLP levels for diagnosis (266). Clinical phenotypes of perinatal HPP include skeletal dysplasia, shorter long bones, bowing of long bones, tetraphocomelia, abnormal posturing, abnormal bone ossification, and a restricted dental abnormality with severe dental caries (276). Patients with perinatal or infantile hypophosphatasia and vitamin B6–dependent seizures have high morbidity and mortality in the first 5 years of life (265). B6-dependent seizures in infants with HPP have been attributed to profound deficiency of TNSALP activity, which blocks PLP dephosphorylation to pyridoxal and consequently diminishes GABA synthesis in the brain, but altered B6 metabolism may cause additional clinical complications as well (267). A human recombinant enzyme replacement therapy (asfotase alfa; initially named ENB-0040) has been developed to treat hypophosphatasia, and initial studies have suggested that in adults and adolescents with pediatric-onset hypophosphatasia, treatment is associated with normalization of circulating TNSALP substrate levels and improved functional abilities (264; 122; 121).

(7) Glycosylphosphatidylinositol anchor synthesis defects, including some cases of hyperphosphatasia with mental retardation syndrome 1 (Mabry syndrome; glycosylphosphatidylinositol biosynthesis defect 2) (OMIM #239300) (249; 130), and glycosylphosphatidylinositol biosynthesis defect 18 (OMIM #618143)

(8) Hyperprolinemia type II (OMIM #239510), a rare autosomal recessive disorder of proline metabolism caused by defective delta-pyrroline 5-carboxylate (P5C) dehydrogenase due to mutations in the ALDH4A1 gene (224; 172).

(9) Hyper-beta-alaninemia associated with Cohen syndrome, an autosomal recessive multisystem disorder characterized by facial dysmorphism, microcephaly, intellectual disability, truncal obesity, progressive retinopathy, and intermittent congenital neutropenia (OMIM #216550) (96).

Pyridoxine-dependent epilepsy. Pyridoxine-dependent epilepsy (OMIM #266100), a neonatal-onset epileptic encephalopathy, is characterized typically by neonatal-onset epileptic encephalopathy responsive to pharmacological doses of vitamin B6 but are resistant to standard antiepileptic drugs. Vitamin B6–dependent epilepsies result from various gene defects (involving the genes ALDH7A1, PNPO, ALPL, ALDH4A1, PLPBP as well as defects of the glycosylphosphatidylinositol anchor proteins) that lead to reduced availability of pyridoxal 5'-phosphate, an important cofactor in neurotransmitter and amino acid metabolism (190).

Although seizures are a defining feature of pyridoxine-dependent epilepsy, other disease manifestations (eg, developmental delay and intellectual disability) can vary widely even among affected siblings with early pyridoxine treatment (08; 49). Pyridoxine-dependent epilepsy is associated with neuronal migration abnormalities and other structural brain defects, which persist despite postnatal pyridoxine supplementation and likely contribute to neurodevelopmental impairments (105).

Pyridoxine-dependent epilepsy results from an inherited metabolic defect that is transmitted as an autosomal-recessive trait. Deficiency or dysfunction of the enzyme antiquitin or ATQ1 (also known as α-amino-adipic semialdehyde dehydrogenase; and aldehyde dehydrogenase 7 family, member A1 or ALDH7A1), encoded by the ALDH7A1 gene on chromosome 5q23.2, has been identified as the underlying cause of pyridoxine-dependent epilepsy in most cases (164; 21; 49). This enzyme functions in a critical step in the lysine degradation pathway in the human brain.

In the saccharopine pathway of lysine degradation in the human brain, lysine is converted first to saccharopine by lysine-α-ketoglutarate reductase and then to α-aminoadipic semialdehyde (α-AASA) by α-aminoadipic semialdehyde synthase (AASS); AASA is subsequently converted to α-aminoadipate (AAA) by antiquitin (165; 237; Hallen and Jamie 2013; 54). Antiquitin dysfunction causes an accumulation of the open-chain aldehyde α-AASA and its cyclic form δ1-piperidine-6-carboxylic acid (P6C), which serve as diagnostic markers in urine and plasma (192; 237). P6C binds and inactivates the active form of pyridoxine (ie, pyridoxal 5'-phosphate or PLP) by forming a Knoevenagel condensation product that no longer has the PLP aldehyde group essential for its function as a cofactor (165; 237; 240). In the absence of the functioning coenzyme pyridoxal phosphate, glutamic acid decarboxylase is unable to decarboxylate glutamic acid to GABA, causing depletion of GABA and the resultant clinical manifestations of seizures. Administration of pyridoxine arrests seizures and may also foster normal development. In addition, rare but treatable causes of unexplained epilepsy extending beyond the classical phenotypes may also result from atypical presentations of ALDH7A1 gene mutations (21; 250).

Folinic acid-responsive seizures are also often due to alpha-AASA dehydrogenase deficiency resulting from mutations in the ALDH7A1 gene, and consequently overlap with the major form of pyridoxine-dependent epilepsy (74; 209; 85; 237), though some have mutations in the folate receptor 1 (FOLR1) gene (65; 05) or the syntaxin binding protein 1 (STXBP1) gene (253).

Other cases of pyridoxine-dependent epilepsy result from mutations in different genes (112), including mutations in the molybdenum cofactor synthesis 2 (MOCS2) gene and the potassium voltage-gated channel subfamily Q member 2 (KCNQ2) gene (240; 12; 190). Two cases of KCNQ2-related neonatal epilepsies [a 5-year-old male with a paternally inherited heterozygous mutation (c.1639C> T; p.Arg547Trp) and a 10-year-old female with a de novo heterozygous mutation (c.740C> T; p.Ser247Leu)] benefited from pyridoxine treatment; several potential mechanisms have been proposed (12). Urinary excretion of α-AASA is also increased in molybdenum cofactor and sulfite oxidase deficiencies resulting from mutations in the molybdenum cofactor synthesis 2 (MOCS2) gene (240).

Schematic representation of mechanisms proposed to explain seizure responsiveness to pyridoxine and the potential link with KCNQ2

Several etiopathogenic mechanisms have been proposed to explain the responsiveness of some neonatal seizures to pyridoxine, and particularly to its active form, pyridoxal 5′ phosphate (PLP). PLP acts as a cofactor of several en...

Pyridoxamine 5'-phosphate oxidase deficiency. Pyridoxamine 5'-phosphate oxidase deficiency (PNPOD; OMIM #610090) is caused by homozygous or compound heterozygous mutation in the PNPO gene (OMIM #603287) on chromosome 17q21. Human PNPO has an allosteric pyridoxal 5'-phosphate binding site that plays a crucial role in regulation of the enzyme and consequently in the regulation of vitamin B6 metabolism (20). This condition has also been called PNPO-related neonatal epileptic encephalopathy. To date only about 20 cases have been reported (165; 219; 191; 260). Deficiency of pyridox(am)ine 5’-phosphate oxidase impairs pyridoxal 5’-phosphate synthesis and recycling.

Pyridoxamine 5'-phosphate oxidase deficiency is an autosomal-recessive inborn error of metabolism resulting in vitamin B6 deficiency that manifests with severe neonatal-onset seizures and subsequent encephalopathy (219). Affected individuals are often born premature with fetal distress (ie, low Apgar scores or requiring intubation) to consanguineous parents (165). Patients typically present in the neonatal period with recurrent myoclonic and clonic contractions, tonic jerks, or hemiclonic seizures, accompanied by rolling or rotary eye movements and oxygen desaturation. Seizures typically begin on the first day of life and in the absence of treatment often rapidly progress to status epilepticus. Patients carrying the missense mutation c(674G> A) p(R225 H) of the PNPO gene may have a more severe epileptic phenotype because of their lower residual PNPO activity (145). In addition, some cases reported a faltering or high-pitched cry, hypersalivation, rhythmic orobuccal movements, encephalopathy, and hypertonia. EEG showed burst-suppression patterns or discontinuous tracings (191), though one patient was reported with centrotemporal spikes with rare generalized spike-wave bursts (260).

A wider clinical spectrum has been recognized, with some having recognized onset as late as 5 months (107). Nevertheless, only about 40% were seizure-free with pyridoxine or pyridoxal-5'-phosphate treatment. Two cases had positive results to anticonvulsant therapy for 17 months and more than 8 years. Surviving cases generally have severe neurocognitive delay, but better results are seen in those who respond to pyridoxine.

Biochemical analysis of cerebrospinal fluid and urine suggested aromatic L-amino acid decarboxylase deficiency, though frequently with additional features of raised glycine, threonine, taurine, and histidine, and low arginine; genetic defects in the AADC gene (OMIM #107930) were excluded in these cases. Laboratory studies also show hypoglycemia, acidosis, anemia, leukopenia, thrombocytopenia, and coagulopathy. Serial brain imaging shows progressive hypomyelination and global atrophy.

Patients with pyridoxamine 5'-phosphate oxidase (PNPO) mutations may respond better to treatment with pyridoxal 5'-phosphate than to pyridoxine (191). Seizures typically respond completely or partially to pyridoxine treatment and often dramatically to pyridoxal phosphate. Breakthrough seizures while on pyridoxine develop in more than half of the patients (191). Status epilepticus may occur following replacement of pyridoxine with pyridoxal 5'-phosphate (191). Consequently, some authors have employed initial combination therapy with both pyridoxine and pyridoxal 5'-phosphate followed by gradual taper of pyridoxine (260).

Affected individuals generally had poor clinical outcomes with global developmental delay, autism spectrum disorder, severe neurologic sequelae, and high mortality, particularly if treatment is delayed.

Prenatal diagnosis of pyridoxamine 5'-phosphate oxidase deficiency using chorionic villus sampling after a sibling had been previously diagnosed postnatally (165).

PLP homeostasis protein (PLPHP) deficiency. Biallelic mutations in the PLPBP gene (OMIM *604436) on chromosome 8p11.23 are another cause of vitamin B6-dependent epilepsy (OMIM #617290) (58; 194; 106; 109; 09; 113). The gene product, PLP homeostasis binding protein PLPHP, a homolog of bacterial proline synthetase cotranscribed (PROSC), is likely to be present in both cytoplasm and mitochondria (109). PLPHP has a pyridoxal 5’-phosphate-binding domain but no enzymatic activity.

PLPHP deficiency in humans is manifested by early-onset intractable seizures responsive to pyridoxine or PLP, developmental delay, and structural brain abnormalities, most notably simplified gyral pattern and cyst-like structures adjacent to the anterior horns (58).

PLPHP acts in intracellular homeostatic regulation of pyridoxal 5’-phosphate, presumably as a carrier that prevents pyridoxal 5’-phosphate from reacting with other molecules (including protecting it from intracellular phosphatases) and that supplies it to apo-enzymes (58).

In addition to early-onset B6-dependent epilepsy, developmental delay and intellectual disability of variable severity are common but not universal (106; 09).

PLPHP deficiency in pediatric patient (MRI)

MRI of a patient with PLPHP deficiency at 4.5 years of age. A sagittal T1-weighted image (A) demonstrates a thin corpus callosum. Axial views show patchy bilateral increase in T2 (B) and FLAIR (C, D) signal in the deep white ma...

Some patients may have clusters of paroxysmal events resembling seizures that respond to vitamin B6 but without EEG correlates, raising the possibility of a B6-responsive movement disorder (09).

Paroxysmal events in a 37-year-old man with PLPHP deficiency

Multiple events were recorded during two different hospitalizations when he was 37 years old. "The semiology of the events was relatively stereotyped and consisted of dystonic facial grimacing, posturing of the upper arms, eye bli...

Hyperglycinemia and hyperlactatemia are the most consistently observed biochemical abnormalities (106).

Pyridoxine-responsive homocystinuria. Untreated homocystinuria usually manifests in the first or second decade of life with intellectual disability, myopia, ectopia lentis, skeletal anomalies (resembling Marfan syndrome), and thromboembolic events. Because pyridoxine is a cofactor for the cystathionine beta-synthase enzyme it facilitates the conversion of homocysteine to cysteine (201; 248). Some patients with autosomal recessive homocystinuria from cystathionine synthase deficiency may be treated effectively with high doses of vitamin B6 (173; 269).

Pyridoxine toxicity. In the 1980s multiple authors described sensory neuronopathy (and less commonly a sensorimotor neuropathy) in patients who consumed high doses of pyridoxine (218; 186; 07; 57; 06; 157; 77; 80; 131; 68). Some of these cases were iatrogenic, resulting from pyridoxine treatment of pyridoxine-dependent epilepsy, homocystinuria, mushroom poisoning, and premenstrual syndrome (07; 57; 06; 157; 68). The pyridoxine dose varied from 200 mg to 10 g per day for periods of up to 20 years. Symptoms began 1 month to several years after starting pyridoxine. In a study of B6 levels in a well-characterized cohort of patients with chronic idiopathic axonal polyneuropathy, moderately elevated plasma B6 levels, even in the 100 to 200 μg/L range, were not associated with significantly worse neuropathy signs or symptoms (236). Duration of consumption prior to symptom onset was inversely proportional to dose. In many cases, symptoms partially improved following discontinuation of pyridoxine but many were still left with severe disability.

Animal models of pyridoxine toxicity have been developed in a variety of animals including dogs (127; 45; 43; 275), guinea pigs (271), cats (234), and rats (195). Additional models of acute auditory neuropathy have been studied after massive administrations of pyridoxine (97). Loss of large-size neurons in the dorsal root ganglia on dogs with experimental pyridoxine toxicity is potentially reversible (275) and recovery can be facilitated with beta-nerve growth factor (β-NGF) (43).

The relationship between pyridoxine overdose levels and histological damage has now been well characterized in both humans and animals. Pyridoxine given in large doses selectively destroys large-diameter peripheral sensory nerve fibers, leaving motor fibers intact.

The pathogenic mechanism of pyridoxine toxicity has not been well characterized, but one possibility is that high circulating concentrations of pyridoxine may inhibit pyridoxal kinase, which disrupts GABAergic transmission and results in excitotoxicity, neurodegeneration, and, ultimately, a sensory neuronopathy (90).

Epidemiology

	• Vitamin B6 deficiency is rare because most foods contain the vitamin.
	• Robust quantities of pyridoxine can be found in meats, particularly liver, fish, and chicken; vegetables, such as beans, peas, and tomatoes; fruits, including oranges, bananas, and avocados; and grains, like enriched breads, cereals, and grains.
	• Physiologic availability of pyridoxine depends on dietary supply, intact absorption, and conversion of pyridoxamine and pyridoxine into the active cofactor in the liver.
	• Pregnant and lactating women have higher daily requirements of pyridoxine than the minimum daily requirement for other adults.

Pyridoxine deficiency is often associated with concomitant deficiencies of other water-soluble vitamins (eg, thiamine, riboflavin, niacin, pantothenic acid, biotin, cobalamin, and folic acid) (133). Alarming levels of inadequate intake of B group vitamins, including pyridoxine, have been documented in tribal lactating women from South India (133).

Isolated dietary pyridoxine deficiency is very rare in the United States, in part because most foods contain the vitamin. Robust quantities can be found in meats, particularly liver, fish, and chicken; vegetables, such as beans, peas, and tomatoes; fruits, including oranges, bananas, and avocados; and grains, like enriched breads, cereals, and grains. Physiologic availability depends on dietary supply, intact absorption, and conversion of pyridoxamine and pyridoxine into the active cofactor (ie, pyridoxal 5'-phosphate) in liver (193). In addition, pyridoxine is produced by the gut microflora (211).

In developed countries, acquired pyridoxine deficiency is usually drug induced (eg, isoniazid, hydralazine, penicillamine, levodopa, and some chemotherapeutic drugs) in the absence of an inborn error of metabolism. Some drug-related causes of pyridoxine deficiency interfere with its metabolism (243; 217).

The minimum daily requirement of pyridoxine is approximately 1.5 mg; however, the recommended daily intake by the U.S. National Research Council is 2 mg for adults and 0.3 mg for infants. Pregnant women require an additional 0.1 mg per day, and women that are lactating require an additional 0.7 to 0.8 mg daily (223; 230). The most common supplemental intake is 10 to 25 mg per day; however, high amounts (100 to 200 mg per day or even more) may be recommended for certain conditions.

Low-plasma vitamin B6 levels, measured as pyridoxal 5'-phosphate, are associated with an increased risk of venous thromboembolism (98).

Children with sickle cell disease have significant hyperhomocysteinemia associated with pyridoxine and relative folate deficiencies (19). However, pyridoxine supplementation in people with sickle cell anemia has not been shown to improve hematologic indexes or disease activity.

The estimated incidence of ALDH7A1 gene mutations resulting in pyridoxine-dependent epilepsy is 1 in 64,352 live births (52) whereas earlier studies provided much lower estimates from 1 in 276,000 (28) to between 1 in 400,000 and 1 in 700,000 (22).

In a population-based transnational Norwegian study, the estimated minimum prevalence of pyridoxine-dependent epilepsy was 6.3 per million among children and 1.2 per million among adults (104).

Prevention

	• Prophylactic administration of pyridoxine should be provided when a patient is using certain medications, such as isoniazid and penicillamine.
	• Pyridoxine supplementation of malnourished children treated for tuberculosis is advisable, particularly those who are HIV-infected.
	• In critically ill patients, a large parenteral dose of vitamin B6 supplementation may compensate for the lack of responsiveness of plasma pyridoxal 5'-phosphate to oral vitamin B6 intake and also increase the immune response of such patients.
	• In the absence of a compelling medical indication and a specific prescription by a knowledgeable medical provider, patients should be discouraged from using doses of vitamins exceeding package recommendations and particularly from using over-the-counter formulations of vitamin B6.

Prophylactic administration of pyridoxine should be provided when a patient is using certain medications, such as isoniazid (30 to 450 mg/d, which may be based gram for gram) (207; 254; 229; 153; 258; 142; 46; 255) and penicillamine (100 mg/d). Pyridoxine supplementation of malnourished children treated for tuberculosis is advisable, particularly those who are HIV-infected (46).

In critically ill patients, a large parenteral dose of vitamin B6 supplementation (50 or 100 mg/day for 14 days) may compensate for the lack of responsiveness of plasma pyridoxal 5'-phosphate to oral vitamin B6 intake and may increase the immune response of such patients (38).

In a study of nursing home residents, almost 50% of residents were deficient in vitamin B6 (123). Vitamin supplements were recommended as an effective prophylaxis for deficiency in all elderly people in nursing homes.

Other rare medical conditions, such as cystathionase deficiency, can be treated with large doses of pyridoxine even though they are not due to a pyridoxine deficiency (142).

It is important to recognize an X-linked hereditary sideroblastic anemia early in life as a significant percentage of cases respond to pyridoxine, thus, avoiding long-term complications (88). Plasma vitamin B6 levels should be ordered as a part of the workup of any unexplained anemia before labeling it as "anemia of chronic disease" (198).

When vitamin B6 is administered daily in supraphysiologic doses, neurotoxicity may occur (typically at levels > 100 nmol/L or 25 μg/L) (198). The frequency of overdosage with vitamin B6 has increased in recent years due to an increase in B6 supplementation overuse (29). In the absence of a compelling medical indication and a specific prescription by a knowledgeable medical provider, patients should be discouraged from using doses of vitamins exceeding package recommendations and particularly from using over-the-counter formulations of vitamin B6. When supplementation is deemed necessary, PLP-based supplements are preferred over pyridoxine supplements because PLP has minimal neurotoxicity in neuronal cell viability tests (198). Weekly administration is preferred over daily use because vitamin B6 metabolites have a long half-life.

Diagnostic workup

	• Pyridoxine deficiency can be diagnosed by checking plasma and erythrocyte pyridoxal 5'-phosphate concentrations.
	• EMG studies of patients with pyridoxine deficiency can demonstrate absent or severely reduced sensory nerve action potentials with mild slowing of sensory nerve conduction velocities; compound motor action potential and motor nerve conduction velocity are normal.
	• Sural nerve biopsy of patients with pyridoxine deficiency shows axonal degeneration of both large- and small-diameter myelinated fibers.
	• Pyridoxine-dependent epilepsy or PNPO should be considered in infants with prolonged episodes of mixed, multifocal, myoclonic, or tonic symptoms, particularly when associated with grimacing and abnormal eye movements.
	• In children with neonatal- or early-infantile-onset seizures, pyridoxine-dependent epilepsy can be confirmed by elevated urinary, plasma, or cerebrospinal fluid alpha aminoadipic-6-semialdehyde (α-AASA) levels and genetic testing for ALDH7A1 mutations.
	• Confusion with other inborn errors of metabolism has produced delays in initiating vitamin B6 in patients with PLPBP deficiency.
	• EEG findings in neonates and infants with pyridoxine-dependent seizures are characterized by repetitive runs of high-voltage, generalized, bilateral, synchronous 1 to 4 Hz spikes, and sharp wave bursts.
	• Normalizing EEG findings or causing clinical cessation of seizures by injecting 100 mg of intravenous pyridoxine identifies pyridoxine-dependent and pyridoxine-responsive seizures.
	• Vitamin B6 toxicity does not require laboratory or other tests.

Pyridoxine deficiency. Pyridoxine deficiency can be diagnosed by checking plasma and erythrocyte pyridoxal 5'-phosphate concentrations. The reference range for pyridoxal phosphate (PLP), the biologically active form of vitamin B6, is 550 µg/L.

Other biochemical and metabolic tests are employed in research studies to assess pyridoxine status but are not generally needed in clinical practice. These include the erythrocyte aspartate aminotransferase activity coefficient (a long-term indicator of functional pyridoxine status), net homocysteine increase in response to a methionine load test, 24-hour urinary xanthurenic acid excretion in response to a tryptophan load test, and urinary 4-pyridoxic acid levels (to examine the impact of pyridoxine treatment on vitamin B6 excretion) (40).

Hematologic indexes may indicate the presence of a hypochromic-microcytic anemia with normal iron levels. Patients with inherited sideroblastic anemias have marked red blood cell dimorphism, anisocytosis, and poikilocytosis.

EMG studies of patients with pyridoxine deficiency can demonstrate absent or severely reduced sensory nerve action potentials with mild slowing of sensory nerve conduction velocities. Compound motor action potential and motor nerve conduction velocity are normal.

Sural nerve biopsy of patients with pyridoxine deficiency shows axonal degeneration of both large- and small-diameter myelinated fibers. Clinical neurophysiologic testing like EMG or EEG can be obtained based on the underlying symptoms. Some patients may develop small fiber neuropathy and dysautonomia and autonomic testing may be helpful in selected cases (17).

Neonatal epileptic encephalopathy. Pyridoxine-dependent epilepsy or PNPO should be considered in infants with prolonged episodes of mixed, multifocal, myoclonic, or tonic symptoms, particularly when associated with grimacing and abnormal eye movements (219).

In neonates with therapy-resistant seizures, a diagnostic trial with pyridoxine, 30 mg/kg per day in two single dosages over 3 consecutive days, is recommended (67). If ineffective, a trial of pyridoxal 5ʹ-phosphate, 30 to 50 mg/kg per day in four to six single dosages, can be considered at the discretion of the treating physician.

Biomarkers for several genetic disorders associated with vitamin B6-dependent epilepsies (ALDH7A1 deficiency, PNPO deficiency, ALPL deficiency causing congenital hypophosphatasia, ALDH4A1 deficiency, and glycosylphosphatidylinositol anchoring defects with hyperphosphatasia) can be detected in plasma or urine, whereas there is no biomarker to test for PLPHP deficiency (Table 1) (190).

Table 1. Biomarkers of Treatable Inborn Errors of Metabolism with Pyridoxine-Responsive Epilepsy

Disorder	Gene	Urine	Plasma	CSF
Antiquitin deficiency	ALDH7A1	Increased AASA, P6C, PA*; Inconsistently elevated vanillactate	Increased PA, 2-OPP*	Increased AASA, P6C; Deceased PLP; Secondary NT abnormalities
PNPO deficiency	PNPO	Inconsistently elevated vanillactate	Increased pyridoxamine	Deceased PLP; Secondary NT abnormalities
Congenital hypophosphatasia	ALPL		Decreased AP; Increased Ca and Ph
PLPHP deficiency	PLPBP
Hyperprolinemia type 2	ALDH4A1	Increased P5C	Increased proline
Abbreviations: 2-OPP: 2S,6S-/2S,6R-oxopropylpiperidine-2-carboxylic acid; AASA: alpha-aminoadipic semialdehyde; AP: alkaline phosphatase; Ca: calcium; CSF: cerebrospinal fluid; NT: neurotransmitters; P5C: L-delta1-pyrroline-5-carboxylate; P6C: L-delta1-piperidine-6-carboxylate; PA: pipecolic acid; Ph: phosphorus; PLP: pyridoxal 50-phosphate * So far only detected by liquid chromatography with tandem mass spectrometry (LC-MS-MS) metabolome analysis
Adapted from: (89; 190)

In children with neonatal- or early-infantile-onset seizures, pyridoxine-dependent epilepsy can be confirmed by elevated urinary, plasma, or cerebrospinal fluid alpha aminoadipic-6-semialdehyde (α-AASA) levels and genetic testing for ALDH7A1 mutations. Low cerebrospinal fluid pyridoxal concentrations may be better than low cerebrospinal fluid pyridoxal 5'-phosphate concentrations as an indicator of pyridoxal 5'-phosphate deficiency in the brain in vitamin B6-dependent epilepsy (03). Urinary screening for α-AASA accumulation is a reliable tool to diagnose pyridoxine-dependent epilepsy and should be included in the evaluation of patients with neonatal epileptic encephalopathy, as well as those with later-onset seizures (28; 192; 74; 182). α-AASA is in spontaneous equilibrium with its cyclic form δ1-piperideine-6-carboxylate (P6C), a molecule with a heterocyclic ring structure (241); the diagnostic utility of assessments of urinary P6C is comparable to that of α-AASA (241).

Homozygous or compound heterozygous mutations in the ALDH7A1 gene have been identified in most patients with pyridoxine-dependent epilepsy (165; 214; 103). ALDH7A1 gene analysis also provides a means for prenatal diagnosis of this condition (165). Structural brain malformations can occur with pyridoxine-dependent epilepsy and should not preclude evaluation for genetic causes (103).

Confusion with other inborn errors of metabolism has produced delays in initiating vitamin B6 in patients with PLPBP deficiency (106; 109): two cases were initially misdiagnosed as mitochondrial encephalopathy because of persistent lactic acidemia and overlapping clinical, neuroradiological, and laboratory features (ie, persistent lactic acidemia) and another case was initially misdiagnosed as glycine encephalopathy because of glycine elevation in plasma (106). Neither of the cases misdiagnosed as mitochondrial encephalopathy had a vitamin B6 trial and both ended fatally. In the case misdiagnosed as glycine encephalopathy, vitamin B6 treatment was not considered and instead the patient was treated unhelpfully with sodium benzoate and dextromethorphan (106). Because a metabolic biomarker for early detection of PLPBP deficiency is still lacking (106), and as the clinical and metabolic presentation is not specific, diagnostic confirmation depends on assessing response to an early vitamin B6 treatment trial in patients with early epileptic encephalopathy and on genetic testing (106).

In neonates with unexplained early onset intractable seizures, lumbar puncture and cerebrospinal fluid metabolite analysis can be helpful in the differential diagnosis of inborn errors of metabolism that lead to infantile epilepsy (252; 101).

EEG findings in neonates and infants with pyridoxine-dependent seizures are characterized by repetitive runs of high-voltage, generalized, bilateral, synchronous 1 to 4 Hz spikes and sharp wave bursts. Normalizing EEG findings or causing clinical cessation of seizures by injecting 100 mg of intravenous pyridoxine identifies pyridoxine-dependent and pyridoxine-responsive seizures.

Pyridoxine toxicity. Vitamin B6 toxicity does not require laboratory or other tests.

Management

	• Although the minimum daily requirement of pyridoxine is only approximately 2 mg in adults, 50 mg/d or more may be required for successful therapy in the deficiency states.
	• One needs to be cautious as supplemental therapy with doses greater than 50 mg/d for a prolonged duration may be harmful.
	• Given that permanent disabling sensory ataxia may develop with pyridoxine administration, sometimes even with modest doses, it is prudent to avoid prescribing (or using) this medication as symptomatic therapy without a clear and compelling indication, especially when potential marginal benefits do not outweigh the serious risks of permanent harm.
	• A trial of pyridoxine is recommended in all patients with the onset of seizures before 18 months of age, regardless of type.
	• There is currently no specific antidote for the treatment of pyridoxine intoxication: neither emesis, lavage, nor administration of activated charcoal changed the ultimate outcome of pyridoxine-poisoned patients. Therefore, it remains essential to recognize the signs of toxicity and use pyridoxine only for essential indications with appropriate dosing.

The goals of pharmacotherapy are to reduce morbidity and to prevent complications. Although the minimum daily requirement of pyridoxine is only approximately 2 mg in adults, 50 mg/d or more may be required for successful therapy in the deficiency states. However, one needs to be cautious as supplemental therapy with doses greater than 50 mg/d for a prolonged duration may be harmful.

Pyridoxine supplementation has been previously advocated for use by bodybuilders and for the treatment of premenstrual syndrome (135), carpal tunnel syndrome (16), tardive dyskinesia (141), childhood autism, and attention deficit hyperactivity disorder, all with at best variable results.

Given that permanent disabling sensory ataxia may develop with pyridoxine administration, sometimes even with modest doses, it is prudent to avoid prescribing (or using) this medication as symptomatic therapy without a clear and compelling indication, especially when potential marginal benefits do not outweigh the serious risks of permanent harm.

Neonatal epileptic encephalopathy. A trial of pyridoxine is recommended in all patients with the onset of seizures before 18 months of age, regardless of type (86; 106). Seizures typically cease within an hour of the administration of 50 to 100 mg of pyridoxine and remain controlled by 5 to 10 mg/kg per day of pyridoxine. Lifelong therapy is required (85). Pyridoxal 5'-phosphate may benefit patients at risk for pyridoxine-dependent epilepsy who do not respond to pyridoxine (219; 94). Because occasional patients with later diagnosis by molecular studies may fail short-term trials of pyridoxine, a prolonged course of pyridoxine therapy is justified, regardless of the initial therapeutic response, to identify delayed responders in infants with drug-refractory epilepsy of no apparent etiology (42).

Pyridoxine-dependent epilepsy, pyridoxamine 5’-phosphate oxidase deficiency, and pyridoxal phosphate-binding protein deficiency are rare diseases that necessitate rapid diagnosis and appropriate treatment. Because the results of genetic and biochemical diagnostic tests are not available for at least several hours, immediate administration of pyridoxine and pyridoxal 5’-phosphate is recommended to make a preliminary diagnosis (219; 106). However, pyridoxal 5’-phosphate is not licensed in many countries and often not readily available in hospitals (219; 238). PLP food supplements are regulated less stringently than medication and may prove to be of insufficient effectiveness and safety (238).

Treatment with folinic acid should be considered in neonatal seizures of unknown origin that do not respond to pyridoxine or manifest only a transient response to pyridoxine (252; 73; 178). Some have advocated treatment with both pyridoxine and folinic acid for patients with antiquitin (alpha-AASA dehydrogenase) deficiency (74).

Patients with confirmed antiquitin deficiency should have adjunct treatment with a lysine-restricted diet unless treatment with pyridoxine alone has resulted in complete symptom resolution, including normal behavior and development (74; 256; 151; 55). Lysine restriction should be started as early as possible, but the optimal duration of dietary restriction is undetermined (256). Long-term outcome can be improved if early therapy includes combination of pyridoxine/arginine supplementation and a lysine-restricted diet (149; 151).

Table 2. Pyridoxine Dosing Based on Underlying Indications

Adult
	• Gyromitra poisoning: 25 mg/kg intravenously over 15 to 30 minutes, repeat when necessary (total dose 15 to 20 g/d) • Cirrhosis: 50 mg/d by mouth • Hemodialysis: 5 to 50 mg/d by mouth • Peritoneal dialysis or chronic renal failure: 2.5 to 5 mg/d by mouth • Sideroblastic anemia: 50 to 600 mg/d by mouth • Homocystinuria or homocystinemia: 100 to 500 mg/d by mouth • Pyridoxine-dependent seizures: 100 mg/d by mouth
Pediatric
	• Pyridoxine-dependent seizures
		- Neonates with seizures: 50 to 100 mg intravenous or intramuscular as a single dose - Infants with pyridoxine-responsive seizures: 50 to 100 mg by mouth four times daily (with no other identifiable cause) - Children without neuritis: 5 to 25 mg by mouth four times daily for 3 weeks, then 1.5 to 2.5 mg by mouth four times daily - Children with neuritis: 10 to 50 mg by mouth four times daily for 3 weeks, then 1 to 2 mg by mouth four times daily
	• Not established for cirrhosis, hemodialysis, peritoneal dialysis, and chronic renal failure

Pyridoxine toxicity. There is currently no specific antidote for the treatment of pyridoxine intoxication (126; 142). Neither emesis, lavage, nor administration of activated charcoal changed the ultimate outcome of pyridoxine-poisoned patients. Therefore, it remains essential to recognize the signs of toxicity and use pyridoxine only for essential indications with appropriate dosing.

Media

References

01: Adams P, White C. Isoniazid-induced encephalopathy. Lancet 1965;1(7387):680-2. PMID 14258550
02: Adelekan DA, Adekile AD, Thurnham DI. Dependence of pyridoxine metabolism on riboflavin status in sickle cell patients. Am J Clin Nutr 1987;46(1):86-90. PMID 3604973
03: Akiyama T, Hyodo Y, Hasegawa K, et al. Pyridoxal in the cerebrospinal fluid may be a better indicator of vitamin B6-dependent epilepsy than pyridoxal 5'-phosphate. Pediatr Neurol. 2020;113:33-41. PMID 32980745
04: Alao AO, Yolles JC. Isoniazid-induced psychosis. Ann Pharmacother 1998;32(9):889-91. PMID 9762376
05: Al-Baradie RS, Chaudhary MW. Diagnosis and management of cerebral folate deficiency. A form of folinic acid-responsive seizures. Neurosciences (Riyadh) 2014;19(4):312-6. PMID 25274592
06: Albin RL, Albers JW. Long-term follow-up of pyridoxine-induced acute sensory neuropathy-neuronopathy. Neurology 1990;40(8):1319. PMID 2166252
07: Albin RL, Albers JW, Greenberg HS, et al. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology 1987;37(11):1729-32. PMID 2823181
08: Alfadhel M, Sirrs S, Waters PJ, et al. Variability of phenotype in two sisters with pyridoxine dependent epilepsy. Can J Neurol Sci 2012;39(4):516-9. PMID 22728861
09: Alsubhi S, Osterman B, Chrestian N, Dubeau F, Buhas D, Srour M. Case report: PLPHP deficiency, a rare but important cause of B6-responsive disorders: a report of three novel individuals and review of 51 cases. Front Neurol 2022;13:913652. PMID 36324377
10: Alvarez FG, Guntupalli KK. Isoniazid overdose: four case reports and review of the literature. Intensive Care Med 1995;21(8):641-4. PMID 8522667
11: Ames EG, Scott AJ, Pappas KB, Moloney SM, Conway RL, Ahmad A. A cautionary tale of pyridoxine toxicity in cystathionine beta-synthase deficiency detected by two-tier newborn screening highlights the need for clear pyridoxine dosing guidelines. Am J Med Genet A 2020;182(11):2704-8. PMID 32820583
12: Amore G, Butera A, Spoto G, et al. KCNQ2-related neonatal epilepsy treated with vitamin B6: a report of two cases and literature review. Front Neurol 2022;13:826225. PMID 35401395
13: Anonymous. Isoniazid and pyridoxine metabolism. Br Med J 1955;1:1203. PMID 14363840
14: Anonymous. The vitamin B6 requirement in oral contraceptive users. Nutr Rev 1979;37(11):344-5. PMID 394035
15: Asnis DS, Bhat JG, Melchert AF. Reversible seizures and mental status changes in a dialysis patient on isoniazid preventive therapy. Ann Pharmacother 1993;27(4):444-6. PMID 8477121
16: Aufiero E, Stitik TP, Foye PM, Chen B. Pyridoxine hydrochloride treatment of carpal tunnel syndrome: a review. Nutr Rev 2004;62(3):96-104. PMID 15098856
17: Bacharach R, Lowden M, Ahmed A. Pyridoxine toxicity small fiber neuropathy with dysautonomia: a case report. J Clin Neuromuscul Dis 2017;19(1):43-6. PMID 28827489
18: Badrinath M, Chen P, John S. Isoniazid toxicity. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2024. PMID 30285383
19: Balasa VV, Kalinyak KA, Bean JA, Stroop D, Gruppo RA. Hyperhomocysteinemia is associated with low plasma pyridoxine levels in children with sickle cell disease. J Pediatr Hematol Oncol 2002;24(5):374-9. PMID 12142786
20: Barile A, Nogués I, di Salvo ML, Bunik V, Contestabile R, Tramonti A. Molecular characterization of pyridoxine 5'-phosphate oxidase and its pathogenic forms associated with neonatal epileptic encephalopathy. Sci Rep 2020;10(1):13621. PMID 32788630
21: Baumgart A, Spiczak SV, Verhoeven-Duif NM, et al. Atypical Vitamin B6 deficiency: a rare cause of unexplained neonatal and infantile epilepsies. J Child Neurol 2014;29(5):704-7. PMID 24114605
22: Bennett CL, Huynh HM, Chance PF, Glass IA, Gospe SM Jr. Genetic heterogeneity for autosomal recessive pyridoxine-dependent seizures. Neurogenetics 2005;6(3):143-9. PMID 16075246
23: Biehl JP, Sklavem JH. Toxicity of isoniazid. Am Rev Tuberc 1953;68(2):296-7. PMID 13065704
24: Biehl JP, Vilter RW. Effects of isoniazid on pyridoxine metabolism. J Am Med Assoc 1954a;156(17):1549-52. PMID 13211282
25: Biehl JP, Vilter RW. Effect of isoniazid on vitamin B6 metabolism; its possible significance in producing isoniazid neuritis. Proc Soc Exp Biol Med 1954b;85(3):389-92. PMID 13167078
26: Blanchard PD, Yao JD, McAlpine DE, Hurt RD. Isoniazid overdose in the Cambodian population of Olmsted County, Minnesota. JAMA 1986;256(22):3131-3. PMID 3783848
27: Blumberg EA, Gil RA. Cerebellar syndrome caused by isoniazid. DICP 1990;24(9):829-31. PMID 2260338
28: Bok LA, Struys E, Willemsen MA, Been JV, Jakobs C. Pyridoxine-dependent seizures in Dutch patients: diagnosis by elevated urinary alpha-aminoadipic semialdehyde levels. Arch Dis Child 2007;92(8):687-9. PMID 17088338
29: Bossard V, Bourmeyster N, Pasini S, et al. Problematic rise of vitamin B6 supplementation overuse and potential risk to bariatric surgery patients. Nutrition 2022;102:111738. PMID 35810581
30: Bossé TR, Donald EA. The vitamin B6 requirement in oral contraceptive users. I. Assessment by pyridoxal level and transferase activity in erythrocytes. Am J Clin Nutr 1979;32(5):1015-23. PMID 433818
31: Brenner A, Wapnir RA. A pyridoxine-dependent behavioral disorder unmasked by isoniazid. Am J Dis Child 1978;132(8):773-6. PMID 150790
32: Brent J, Vo N, Kulig K, Rumack BH. Reversal of prolonged isoniazid-induced coma by pyridoxine. Arch Intern Med 1990;150(8):1751-3. PMID 2152443
33: Brown A, Mallett M, Fiser D, Arnold WC. Acute isoniazid intoxication: reversal of CNS symptoms with large doses of pyridoxine. Pediatr Pharmacol 1984;4(3):199-202. PMID 6493843
34: Brown CV. Acute isoniazid poisoning. Am Rev Respir Dis 1972;105(2):206-16. PMID 5009799
35: Caksen H, Odabas D, Erol M, Anlar O, Tuncer O, Atas B. Do not overlook acute isoniazid poisoning in children with status epilepticus. J Child Neurol 2003;18(2):142-3. PMID 12693784
36: Cash JM, Zawada ET Jr. Isoniazid overdose. Successful treatment with pyridoxine and hemodialysis. West J Med 1991;155(6):644-6. PMID 1812641
37: Castagnet S, Blasco H, Vourc'h P, Andres CR, Praline J. [Chronic demyelinating polyneuropathy and B6 hypervitaminosis.] [Article in French] Rev Med Interne 2010;31(12):e1-e3. PMID 20627481
38: Cheng CH, Chang SJ, Lee BJ, Lin KL, Huang YC. Vitamin B6 supplementation increases immune responses in critically ill patients. Eur J Clin Nutr 2006;60(10):1207-13. PMID 16670691
39: Cheung WC, Lo CY, Lo WK, Ip M, Cheng IK. Isoniazid induced encephalopathy in dialysis patients. Tuber Lung Dis 1993;74(2):136-9. PMID 8324207
40: Chiang EP, Selhub J, Bagley PJ, Dallal G, Roubenoff R. Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. Arthritis Res Ther 2005a;7(6):R1404-11. PMID 16277693
41: Chiang EP, Smith DE, Selhub J, Dallal G, Wang YC, Roubenoff R. Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther 2005b;7(6):R1254-62. PMID 16277678
42: Chidambaram AC, Talwar M, Kasinathan A, Gulati R, Selvan T. Pyridoxine therapy: not just the dose, the duration matters too. J Pediatr Genet 2020;12(1):73-5. PMID 36684551
43: Cho HK, Kim W, Lee KY, et al. Beta-nerve growth factor gene therapy alleviates pyridoxine-induced neuropathic damage by increasing doublecortin and tyrosine kinase A in the dorsal root ganglion. Neural Regen Res 2020;15(1):162-8. PMID 31535665
44: Chongtham DS, Ram T, Jain S. Acute isoniazid poisoning: presenting as seizure. Indian J Chest Dis Allied Sci 1997;39(4):255-7. PMID 9654823
45: Chung JY, Choi JH, Hwang CY, Youn HY. Pyridoxine induced neuropathy by subcutaneous administration in dogs. J Vet Sci 2008;9(2):127-31. PMID 18487933
46: Cilliers K, Labadarios D, Schaaf HS, et al. Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid. Acta Paediatr 2010;99(5):705-10. PMID 20146723
47: Citak A, Kaya O, Uçsel R, Karaböcüoğlu M, Uzel N. Acute isoniazid neurotoxicity in childhood. Turk J Pediatr 2002;44(1):54-7. PMID 11858381
48: Clayton PT. B6-responsive disorders: a model of vitamin dependency. J Inherit Metab Dis 2006;29(2-3):317-26. PMID 16763894
49: Coci EG, Codutti L, Fink C, et al. Novel homozygous missense mutation in ALDH7A1 causes neonatal pyridoxine dependent epilepsy. Mol Cell Probes 2017;32:18-23. PMID 27856333
50: Cohen LK, George W, Smith R. Isoniazid-induced acne and pellagra: occurrence in slow inactivators of isoniazid. Arch Dermatol 1974;109(3):377-81. PMID 4273616
51: Corson SL. Contraceptive steroid effects on nonreproductive organ systems. J Reprod Med 1986;31(9 Suppl):865-78. PMID 3772906
52: Coughlin CR 2nd, Swanson MA, Spector E, et al. The genotypic spectrum of ALDH7A1 mutations resulting in pyridoxine dependent epilepsy: a common epileptic encephalopathy. J Inherit Metab Dis 2019;42(2):353-61. PMID 30043187
53: Coursin DB. Convulsive seizures in infants with pyridoxine-deficient diet. J Am Med Assoc 1954;154(5):406-8. PMID 13117629
54: Crowther LM, Mathis D, Poms M, Plecko B. New insights into human lysine degradation pathways with relevance to pyridoxine-dependent epilepsy due to antiquitin deficiency. J Inherit Metab Dis 2019;42(4):620-8. PMID 30767241
55: Coughlin CR 2nd, Tseng LA, Abdenur JE, et al. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis 2021;44(1):178-92. PMID 33200442
56: Dalakas MC. Chronic idiopathic ataxic neuropathy. Ann Neurol 1986;19(6):545-54. PMID 3014995
57: Dalton K, Dalton MJ. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand 1987;76(1):8-11. PMID 3630649
58: Darin N, Reid E, Prunetti L, et al. Mutations in PROSC disrupt cellular pyridoxal phosphate homeostasis and cause vitamin-B6-dependent epilepsy. Am J Hum Genet 2016;99(6):1325-37. PMID 27912044
59: Darvay A, Basarab T, McGregor JM, Russell-Jones R. Isoniazid induced pellagra despite pyridoxine supplementation. Clin Exp Dermatol 1999;24(3):167-9. PMID 10354170
60: Dastur DK, Santhadevi N, Quadros EV, et al. The B-vitamins in malnutrition with alcoholism. A model of intervitamin relationships. Br J Nutr 1976;36(2):143-59. PMID 182198
61: Dave HN, Eugene Ramsay R, Khan F, Sabharwal V, Irland M. Pyridoxine deficiency in adult patients with status epilepticus. Epilepsy Behav 2015;52(Pt A):154-8. PMID 26418265
62: de Kruijk JR, Notermans NC. [Sensory disturbances caused by multivitamin preparations.] [Article in Dutch] Ned Tijdschr Geneeskd 2005;149(46):2541-4. PMID 16320661
63: Demiroglu H, Dündar S. Vitamin B6 responsive sideroblastic anaemia in a patient with tuberculosis. Br J Clin Pract 1997;51:51-2. PMID 9158274
64: Devadatta S, Gangadharam PR, Andrews RH, Fox W, Ramakrishnan CV, Selkon JB, Velu S. Peripheral neuritis due to isoniazid. Bull World Health Organ 1960;23:587-98. PMID 13722334
65: Dill P, Schneider J, Weber P, et al. Pyridoxal phosphate-responsive seizures in a patient with cerebral folate deficiency (CFD) and congenital deafness with labyrinthine aplasia, microtia and microdontia (LAMM). Mol Genet Metab 2011;104(3):362-8. PMID 21752681
66: Donald EA, Bossé TR. The vitamin B6 requirement in oral contraceptive users. II. Assessment by tryptophan metabolites, vitamin B6, and pyridoxic acid levels in urine. Am J Clin Nutr 1979;32(5):1024-32. PMID 433819
67: Dulac O, Plecko B, Gataullina S, Wolf NI. Occasional seizures, epilepsy, and inborn errors of metabolism. Lancet Neurol 2014;13(7):727-39. PMID 24943345
68: Echaniz-Laguna A, Mourot-Cottet R, Noel E, Chanson JB. Regressive pyridoxine-induced sensory neuronopathy in a patient with homocystinuria. BMJ Case Rep 2018;2018. PMID 29954767
69: Espinoza AC, Wright MA, Candee MS, Trandafir C, Nelson GR. Child neurology: late-onset vitamin B6-dependent epilepsy identified by rapid genome sequencing. Neurology 2021;96(19):911-4. PMID 33766999
70: Farmania R, Gupta A, Ankur K, Chetry S, Sharma S. Complexities of pyridoxine response in PNPO deficiency. Epilepsy Behav Rep 2021;16:100443. PMID 33981986
71: Festin M. Nausea and vomiting in early pregnancy. BMJ Clin Evid 2014;2014. PMID 24646807
72: Finsterer J, Scorza FA, Scorza CA, Fiorini AC. Parkinson-related neuropathy. Clinics (Sao Paulo) 2021;76:e2675. PMID 33567051
73: Frye RE, Donner E, Golja A, Rooney CM. Folinic acid-responsive seizures presenting as breakthrough seizures in a 3-month-old boy. J Child Neurol 2003;18(8):562-9. PMID 13677584
74: Gallagher RC, Van Hove JL, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol 2009;65(5):550-6. PMID 19142996
75: Gammon GD, King G, Burge FW. Neural toxicity in tubercular patients treated with isonicotinic acid hydrazide. Trans Am Neurol Assoc 1953;3(78th Meeting):137-9. PMID 13179193
76: Garrett CR. Optic neuritis in a patient on ethambutol and isoniazid evaluated by visual evoked potentials: case report. Mil Med 1985;150(1):43-6. PMID 3920559
77: Gdynia HJ, Müller T, Sperfeld AD, et al. Severe sensorimotor neuropathy after intake of highest dosages of vitamin B6. Neuromuscul Disord 2008;18(2):156-8. PMID 18060778
78: Gerlach AT, Thomas S, Stawicki SP, Whitmill ML, Steinberg SM, Cook CH. Vitamin B6 deficiency: a potential cause of refractory seizures in adults. JPEN J Parenter Enteral Nutr 2011;35(2):272-5. PMID 21378258
79: Ghatge MS, Al Mughram M, Omar AM, Safo MK. Inborn errors in the vitamin B6 salvage enzymes associated with neonatal epileptic encephalopathy and other pathologies. Biochimie 2021;183:18-29. PMID 33421502
80: Ghavanini AA, Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess. J Clin Neuromuscul Dis 2014;16(1):25-31. PMID 25137514
81: Gibaud M, Barth M, Lefranc J, et al. West Syndrome is an exceptional presentation of pyridoxine- and pyridoxal phosphate-dependent epilepsy: data from a French cohort and review of the literature. Front Pediatr 2021;9:621200. PMID 33748042
82: Gilhotra R, Malik SK, Singh S, Sharma BK. Acute isoniazid toxicity--report of 2 cases and review of literature. Int J Clin Pharmacol Ther Toxicol 1987;25(5):259-61. PMID 3596852
83: Gillmer MD, Mazibuko D. Pyridoxine treatment of chemical diabetes in pregnancy. Am J Obstet Gynecol 1979;133(5):499-502. PMID 443288
84: González-Gay MA, Sánchez-Andrade A, Agüero JJ, Alonso MD, Rodriguez E, Criado JR. Optic neuritis following treatment with isoniazid in a hemodialyzed patient. Nephron 1993;63:360. PMID 8446281
85: Gospe SM Jr. Neonatal vitamin-responsive epileptic encephalopathies. Chang Gung Med J 2010;33(1):1-12. PMID 20184790
86: Goutieres F, Aicardi J. Atypical presentations of pyridoxine-dependent seizures: a treatable cause of intractable epilepsy in infants. Ann Neurol 1985;17(2):117-20. PMID 3977296
87: Greentree LB. Inhibition of prolactin by pyridoxine. Am J Obstet Gynecol 1979;135(2):280-1. PMID 474683
88: Gupta SK, Rao S, Kar R, Tyagi S, Pati HP. Congenital sideroblastic anemia: a report of two cases. Indian J Pathol Microbiol 2009;52(3):424-6. PMID 19679982
89: Guzel Nur B, Çelmeli G, Manguoğlu E, Soyucen E, Bircan İ, Mıhçı E. Pyridoxine-responsive seizures in infantile hypophosphatasia and a novel homozygous mutation in ALPL gene. J Clin Res Pediatr Endocrinol 2016;8(3):360-4. PMID 27086862
90: Hadtstein F, Vrolijk M. Vitamin B-6-induced neuropathy: exploring the mechanisms of pyridoxine toxicity. Adv Nutr 2021;12(5):1911-29. PMID 33912895
91: Haridasan S, Madhyastha R, Ghosn M, et al. Refractory seizures in a dialysis patient and a vitamin consigned to oblivion. Clin Nephrol Case Stud 2023;11:132-5. PMID 37705940
92: Harraway JR, Sheard JM, Soule SJ, Florkowski CM, George PM. Autosomal recessive adult-onset hypophosphatasia. Pathology 2005;37(6):563-5. PMID 16373239
93: Harris SA, Folkers K. Synthesis of vitamin B-6. J Am Chem Soc 1939;61:1245-7.
94: Hartmann H, Fingerhut M, Jakobs C, Plecko B. Status epilepticus in a neonate treated with pyridoxine because of a familial recurrence risk for antiquitin deficiency: pyridoxine toxicity. Dev Med Child Neurol 2011;53(12):1150-3. PMID 21707605
95: Hassel B, Rogne AG, Hope S. Intellectual disability associated with pyridoxine-responsive epilepsies: the need to protect cognitive development. Front Psychiatry 2019;10:116. PMID 30930802
96: Higgins JJ, Kaneski CR, Bernardini I, Brady RO, Barton NW. Pyridoxine-responsive hyper-beta-alaninemia associated with Cohen's syndrome. Neurology 1994;44(9):1728-32. PMID 7936305
97: Hong BN, Yi TH, Kim SY, Kang TH. High-dosage pyridoxine-induced auditory neuropathy and protection with coffee in mice. Biol Pharm Bull 2009;32(4):597-603. PMID 19336890
98: Hron G, Lombardi R, Eichinger S, Lecchi A, Kyrle PA, Cattaneo M. Low vitamin B6 levels and the risk of recurrent venous thromboembolism. Haematologica 2007;92(9):1250-3. PMID 17666362
99: Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 1954;70(2):266-73. PMID 13180863
100: Hunt AD Jr, Stokes J Jr, McCrory WW, Stroud HH. Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics 1954;13(2):140-5. PMID 13133562
101: Hyland K, Arnold LA. Value of lumbar puncture in the diagnosis of infantile epilepsy and folinic acid-responsive seizures. J Child Neurol 2002;17 Suppl 3:3S48-55; discussion 3S56. PMID 12597055
102: Ishii N, Nishihara Y. Pellagra encephalopathy among tuberculous patients: its relation to isoniazid therapy. J Neurol Neurosurg Psychiatry 1985;48(7):628-34. PMID 4031907
103: Jain-Ghai S, Mishra N, Hahn C, Blaser S, Mercimek-Mahmutoglu S. Fetal onset ventriculomegaly and subependymal cysts in a pyridoxine dependent epilepsy patient. Pediatrics 2014;133(4):e1092-6. PMID 24664088
104: Jamali A, Kristensen E, Tangeraas T, et al. The spectrum of pyridoxine dependent epilepsy across the age span: a nationwide retrospective observational study. Epilepsy Res 2023;190:107099. PMID 36731270
105: Jansen LA, Hevner RF, Roden WH, Hahn SH, Jung S, Gospe SM Jr. Glial localization of antiquitin: implications for pyridoxine-dependent epilepsy. Ann Neurol 2014;75(1):22-32. PMID 24122892
106: Jensen KV, Frid M, Stödberg T, et al. Diagnostic pitfalls in vitamin B6-dependent epilepsy caused by mutations in the PLPBP gene. JIMD Rep 2019;50(1):1-8. PMID 31741821
107: Jiao X, Gong P, Niu Y, Xu Z, Zhang Y, Yang Z. Analysis for variable manifestations and molecular characteristics of pyridox(am)ine-5'-phosphate oxidase (PNPO) deficiency. Hum Mol Genet 2023;32(11):1765-71. PMID 36106796
108: Jimenez-Lucho VE, del Busto R, Odel J. Isoniazid and ethambutol as a cause of optic neuropathy. Eur J Respir Dis 1987;71(1):42-5. PMID 3115809
109: Johnstone DL, Al-Shekaili HH, Tarailo-Graovac M, et al. PLPHP deficiency: clinical, genetic, biochemical, and mechanistic insights. Brain 2019;142(3):542-59. PMID 30668673
110: Jones WA, Jones GP. Peripheral neuropathy due to isoniazid; report of two cases. Lancet 1953;1(6770):1073-4. PMID 13045527
111: Jugel C, Ehlen F, Taskin B, Marzinzik F, Müller T, Klostermann F. Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs. PLoS One 2013;8(6):e66639. PMID 23818953
112: Kabakus N, Aydin M, Ugur SA, Durukan M, Tolun A. Very-late-onset pyridoxine-dependent seizures not linking to the known 5q31 locus. Pediatr Int 2008;50(5):703-5. PMID 19261126
113: Kalser J, Giuliano F, Peralta M, Plecko B, Bölsterli BK. Infantile spasms without hypsarrhythmia and paroxysmal eye-head movements in an infant with a pyridoxine-dependent epilepsy due to PLPBP/PLPHP deficiency. Neuropediatrics 2023;54(6):422-5. PMID 36577449
114: Kaminiow K, Pająk M, Pająk R, Paprocka J. Pyridoxine-dependent epilepsy and antiquitin deficiency resulting in neonatal-onset refractory seizures. Brain Sci 2021;12(1):65. PMID 35053812
115: Karmon G, Savir H, Zevin D, Levi J. Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment. Ann Ophthalmol 1979;11(7):1013-7. PMID 384871
116: Kass I, Mandel W, Cohen H, Dressler SH. Isoniazid as a cause of optic neuritis and atrophy. J Am Med Assoc 1957;164(16):1740-3. PMID 13448928
117: Katan MB. [How much vitamin B6 is toxic.] [Article in Dutch] Ned Tijdschr Geneeskd 2005;149(46):2545-6. PMID 16320662
118: Kato N, Kimoto A, Zhang P, et al. Relationship of low vitamin B6 status with sarcopenia, frailty, and mortality: a narrative review. Nutrients 2024;16(1):177. PMID 38202006
119: Keeping JA, Searle CW. Optic neuritis following isoniazid therapy. Lancet 1955;269(6884):278. PMID 13243713
120: Khoharo HK, Ansari S, Abro A, Qureshi F. Suicidal Isoniazid poisoning. J Ayub Med Coll Abbottabad 2009;21(2):178-9. PMID 20524502
121: Kishnani PS, Del Angel G, Zhou S, Rush ET. Investigation of ALPL variant states and clinical outcomes: an analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa. Mol Genet Metab 2021;133(1):113-21. PMID 33814268
122: Kishnani PS, Rockman-Greenberg C, Rauch F, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone 2019;121:149-62. PMID 30576866
123: Kjeldby IK, Fosnes GS, Ligaarden SC, Farup PG. Vitamin B6 deficiency and diseases in elderly people--a study in nursing homes. BMC Geriatr 2013;13:13. PMID 23394203
124: Kocabay G, Erelel M, Tutkun IT, Ecder T. Optic neuritis and bitemporal hemianopsia associated with isoniazid treatment in end-stage renal failure. Int J Tuberc Lung Dis 2006;10(12):1418-9. PMID 17171829
125: Kokkada SB, Barthakur R, Natarajan M, Palaian S, Chhetri AK, Mishra P. Ocular side effects of antitubercular drugs - a focus on prevention, early detection and management. Kathmandu Univ Med J (KUMJ) 2005;3(4):438-41. PMID 16449853
126: Krenzelok EP. New developments in the therapy of intoxications. Toxicol Lett 2002;127(1-3):299-305. PMID 12052670
127: Krinke G, Schaumburg HH, Spencer PS, Suter J, Thomann P, Hess R. Pyridoxine megavitaminosis produces degeneration of peripheral sensory neurons (sensory neuronopathy) in the dog. Neurotoxicology 1981;2(1):13-24. PMID 15622720
128: Krishnamurthy DV, Selkon JB, Ramachandran K, et al. Effect of pyridoxine on vitamin B6 concentrations and glutamic-oxaloacetic transaminase activity in whole blood of tuberculous patients receiving high-dosage isoniazid. Bull World Health Organ 1967;36(5):853-70. PMID 4866185
129: Kuhn R, Westphal K, Wendt G, Westphal O. Synthesis of adermine. Naturwissenschaften 1939;27:469-70.
130: Kuki I, Takahashi Y, Okazaki S, et al. Vitamin B6-responsive epilepsy due to inherited GPI deficiency. Neurology 2013;81(16):1467-9. PMID 24049131
131: Kulkantrakorn K. Pyridoxine-induced sensory ataxic neuronopathy and neuropathy: revisited. Neurol Sci 2014;35(11):1827-30. PMID 25056196
132: Kulkarni HS, Keskar VS, Bavdekar SB, Gabhale Y. Bilateral optic neuritis due to isoniazid (INH). Indian Pediatr 2010;47(6):533-5. PMID 20622286
133: Kumar PSS, Gupta A, Desu SS, et al. Alarming levels of inadequate intake of B group vitamins in tribal lactating women from South India. J Public Health Res 2024;13(1):22799036241234036. PMID 38476323
134: Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve 2004;30(3):255-68. PMID 15318336
135: Kwan I, Onwude JL. Premenstrual syndrome. BMJ Clin Evid 2007;2007.pii: 0806. PMID 19454075
136: Labadarios D, Rossouw JE, McConnell JB, Davis M, Williams R. Vitamin B6 deficiency in chronic liver disease--evidence for increased degradation of pyridoxal-5'-phosphate. Gut 1977;18(1):23-7. PMID 838399
137: Laine-Cessac P, Cailleux A, Allain P. Mechanisms of the inhibition of human erythrocyte pyridoxal kinase by drugs. Biochem Pharmacol 1997;54(8):863-70. PMID 9354586
138: Leathem AM, Dorran TJ. Poisoning due to raw Gyromitra esculenta (false morels) west of the Rockies. CJEM 2007;9(2):127-30. PMID 17391587
139: Leklem JE, Brown RR, Rose DP, Linkswiler HM. Vitamin B6 requirements of women using oral contraceptives. Am J Clin Nutr 1975;28(5):535-41. PMID 1130311
140: Lepkovsky S. Crystalline factor I. Science 1938;87(2251):169-70.
141: Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158(9):1511-4. PMID 11532741
142: Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. Eur J Emerg Med 2005;12(2):78-85. PMID 15756083
143: Ling CT, Hegsted DM, Stare FJ. The effect of pyridoxine deficiency on the tryptophan-niacin transformation in rats. J Biol Chem 1948;174(3):803-12. PMID 18871239
144: Lubing HN. Peripheral neuropathy in tuberculosis patients treated with isoniazid. Am Rev Tuberc 1953;68(3):458-61. PMID 13080603
145: Lugli L, Bariola MC, Ori L, Lucaccioni L, Berardi A, Ferrari F. Further delineation of pyridoxine-responsive pyridoxine phosphate oxidase deficiency epilepsy: report of a new case and review of the literature with genotype-phenotype correlation. J Child Neurol 2019;34(14):937-43. PMID 31397616
146: Lumeng L, Li TK. Vitamin B6 metabolism in chronic alcohol abuse. Pyridoxal phosphate levels in plasma and the effects of acetaldehyde on pyridoxal phosphate synthesis and degradation in human erythrocytes. J Clin Invest 1974;53(3):693-704. PMID 4359937
147: Majumdar SK, Shaw GK, O'Gorman P, Aps EJ, Offerman EL, Thomson AD. Blood vitamin status (B1, B2, B6, folic acid and B12) in patients with alcoholic liver disease. Int J Vitam Nutr Res 1982;52(3):266-71. PMID 7174224
148: Mandel W. Pyridoxine and the isoniazid-induced neuropathy. Dis Chest 1959;36:293-6. PMID 14420556
149: Marguet F, Barakizou H, Tebani A, et al. Pyridoxine-dependent epilepsy: report on three families with neuropathology. Metab Brain Dis 2016;31(6):1435-43. PMID 27438048
150: Martinjak-Dvorsek I, Gorjup V, Horvat M, Noc M. Acute isoniazid neurotoxicity during preventive therapy. Crit Care Med 2000;28(2):567-8. PMID 10708202
151: Mastrangelo M, Cesario S. Update on the treatment of vitamin B6 dependent epilepsies. Expert Rev Neurother 2019;19(11):1135-47. PMID 31340680
152: Matsui MS, Rozovski SJ. Drug-nutrient interaction. Clin Ther 1982;4(6):423-40. PMID 7046936
153: Maw G, Aitken P. Isoniazid overdose: a case series, literature review and survey of antidote availability. Clin Drug Investig 2003;23(7):479-85. PMID 17535059
154: McConnell RB, Cheetham HD. Acute pellagra during isoniazid therapy. Lancet 1952;2(6742):959-60. PMID 12991655
155: McCurdy PR, Donohoe RF. Pyridoxine-responsive anemia conditioned by isonicotinic acid hydrazide. Blood 1966;27(3):352-62. PMID 5930800
156: McKenzie SA, Macnab AJ, Katz G. Neonatal pyridoxine- responsive convulsions due to isoniazid therapy. Arch Dis Child 1976;51(7):567-8. PMID 1085609
157: McLachlan RS, Brown WF. Pyridoxine dependent epilepsy. Can J Paediatr Neurol 1995;22(1): 50-1. PMID 7750075
158: McParlin C, O'Donnell A, Robson SC, et al. Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review. JAMA 2016;316(13):1392-401. PMID 27701665
159: Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol 2016;23(3):501-9. PMID 26498913
160: Merrill AH Jr, Henderson JM, Wang E, Codner MA, Hollins B, Millikan WJ. Activities of the hepatic enzymes of vitamin B6 metabolism for patients with cirrhosis. Am J Clin Nutr 1986;44(4):461-7. PMID 3020959
161: Mikalunas V, Fitzgerald K, Rubin H, McCarthy R, Craig RM. Abnormal vitamin levels in patients receiving home total parenteral nutrition. J Clin Gastroenterol 2001;33(5):393-6. PMID 11606856
162: Miller J, Robinson A, Percy AK. Acute isoniazid poisoning in childhood. Am J Dis Child 1980;134(3):290-2. PMID 6965818
163: Miller LT, Johnson A, Benson EM, Woodring MJ. Effect of oral contraceptives and pyridoxine on the metabolism of vitamin B6 and on plasma tryptophan and alpha-amino nitrogen. Am J Clin Nutr 1975;28(8):846-53. PMID 1146743
164: Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010;133(Pt 7):2148-59. PMID 20554659
165: Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006;12(3):307-9. PMID 16491085
166: Minns AB, Ghafouri N, Clark RF. Isoniazid-induced status epilepticus in a pediatric patient after inadequate pyridoxine therapy. Pediatr Emerg Care 2010;26(5):380-1. PMID 20453796
167: Mintzer S, Skidmore CT, Sperling MR. B-vitamin deficiency in patients treated with antiepileptic drugs. Epilepsy Behav 2012;24(3):341-4. PMID 22658435
168: Mitchell D, Wagner C, Stone WJ, Wilkinson GR, Schenker S. Abnormal regulation of plasma pyridoxal 5'-phosphate in patients with liver disease. Gastroenterology 1976;71(6):1043-9. PMID 992265
169: Morris MS, Picciano MF, Jacques PF, Selhub J. Plasma pyridoxal 5'-phosphate in the US population: the National Health and Nutrition Examination Survey, 2003-2004. Am J Clin Nutr 2008;87(5):1446-54. PMID 18469270
170: Morris MS, Sakakeeny L, Jacques PF, Picciano MF, Selhub J. Vitamin B-6 intake is inversely related to, and the requirement is affected by, inflammation status. J Nutr 2010;140(1)103-10. PMID 19906811
171: Morrow LE, Wear RE, Schuller D, Malesker M. Acute isoniazid toxicity and the need for adequate pyridoxine supplies. Pharmacotherapy 2006;26(10):1529-32. PMID 16999664
172: Motte J, Fisse AL, Grüter T, et al. Novel variants in a patient with late-onset hyperprolinemia type II: diagnostic key for status epilepticus and lactic acidosis. BMC Neurol 2019;19(1):345. PMID 31884946
173: Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985;37(1):1-31. PMID 3872065
174: Muhamad R, Akrivaki A, Papagiannopoulou G, Zavridis P, Zis P. The role of vitamin B6 in peripheral neuropathy: a systematic review. Nutrients 2023;15(13):2823. PMID 37447150
175: Mydlik M, Derzsiova K. Vitamin B6 and oxalic acid in clinical nephrology. J Ren Nutr 2010;20(5 Suppl):S95-102. PMID 20797580
176: Natta CL, Reynolds RD. Apparent vitamin B6 deficiency in sickle cell anemia. Am J Clin Nutr 1984;40(2):235-9. PMID 6465055
177: Nelson MC, Zemel BS, Kawchak DA, et al. Vitamin B6 status of children with sickle cell disease. J Pediatr Hematol Oncol 2002;24(6):463-9. PMID 12218594
178: Nicolai J, van Kranen-Mastenbroek VH, Wevers RA, Hurkx WA, Vles JS. Folinic acid-responsive seizures initially responsive to pyridoxine. Pediatr Neurol 2006;34(2):164-7. PMID 16458834
179: Nisar M, Watkin SW, Bucknall RC, Agnew RA. Exacerbation of isoniazid induced peripheral neuropathy by pyridoxine. Thorax 1990;45(5):419-20. PMID 2166360
180: Nolan CM, Elarth AM, Barr HW. Intentional isoniazid overdosage in young Southeast Asian refugee women. Chest 1988;93(4):803-6. PMID 3349838
181: Noguera-Pons R, Borrás-Blasco J, Romero-Crespo I, Antón-Torres R, Navarro-Ruiz A, González-Ferrandez JA. Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother 2005;39(12):2131-5. PMID 16264061
182: Oliveira R, Pereira C, Rodrigues F, et al. Pyridoxine-dependent epilepsy due to antiquitin deficiency: achieving a favourable outcome. Epileptic Disord 2013;15(4):400-6. PMID 24184718
183: Orlowski JP, Paganini EP, Pippenger CE. Treatment of a potentially lethal dose isoniazid ingestion. Ann Emerg Med 1988;17(1):73-6. PMID 3337420
184: Paluszny A, Qiu S. Vitamin B6 toxicity secondary to daily multivitamin use: a case report. Cureus 2023;15(11):e48792. PMID 38098895
185: Parish RA, Brownstein D. Emergency department management of children with acute isoniazid poisoning. Pediatr Emerg Care 1986;2(2):88-90. PMID 3097625
186: Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology 1985;35(10):1466-8. PMID 2993949
187: Pellock JM, Howell J, Kendig EL Jr, Baker H. Pyridoxine deficiency in children treated with isoniazid. Chest 1985;87(5):658-61. PMID 3987378
188: Perkins RP. Failure of pyridoxine to improve glucose tolerance in gestational diabetes mellitus. Obstet Gynecol 1977;50(3):370-2. PMID 896108
189: Piekarski R, Roszmann A, Dulski J, Sławek J. Acute/subacutae demyelinating polyneuropathy in Parkinson's disease patients on levodopa-carbidopa intestinal gel therapy: systematic review with new case report. Neurol Neurochir Pol 2023;57(2):169-76. PMID 36628506
190: Plecko B. On pathways and blind alleys-the importance of biomarkers in vitamin B6-dependent epilepsies. J Inherit Metab Dis 2023;46(5):839-47. PMID 37428623
191: Plecko B, Paul K, Mills P, et al. Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology 2014;82(16):1425-33. PMID 24658933
192: Plecko B, Paul K, Paschke E, et al. Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat 2007;28(1):19-26. PMID 17068770
193: Plecko B, Stockler S. Vitamin B6 dependent seizures. Can J Neurol Sci 2009;36 Suppl 2:S73-7. PMID 19760909
194: Plecko B, Zweier M, Begemann A, et al. Confirmation of mutations in PROSC as a novel cause of vitamin B6-dependent epilepsy. J Med Genet 2017;54(12):809-14. PMID 28391250
195: Poindron P, Piguet P. New Animal Models of Human Neurological Diseases. Vol 2. Basel, Karger: BioValley Monographs, 2008:66-80.
196: Rane S, Elrahi S, Villarreal J, et al. Low serum pyridoxine levels worsen seizure control in adult epilepsy patients. Cureus 2022;14(6):e25669. PMID 35812624
197: Raskin NH, Fishman RA. Pyridoxine-deficiency neuropathy due to hydralazine. N Engl J Med 1965;273(22):1182-5. PMID 5847557
198: Reddy P. Preventing vitamin B6-related neurotoxicity. Am J Ther 2022;29(6):e637-43. PMID 36608063
199: Redleaf PD. Pyridoxine-responsive anemia in a patient receiving isoniazid. Dis Chest 1962;42:222-6. PMID 14490943
200: Reeves RR, Liberto V. Confusion associated with isoniazid-induced pyridoxine deficiency. Psychosomatics 2004;45(6):537-8. PMID 15546832
201: Reish O, Townsend D, Berry SA, Tsai MY, King RA. Tyrosinase inhibition due to interaction of homocyst(e)ine with copper: the mechanism for reversible hypopigmentation in homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1995;57(1):127-32. PMID 7611281
202: Rojo-Sebastian A, González-Robles C, García de Yébenes J. Vitamin B6 deficiency in patients with Parkinson disease treated with levodopa/carbidopa. Clin Neuropharmacol 2020;43(5):151-7. PMID 32947426
203: Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L. Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract 2018;6(2):96-103. PMID 30838307
204: Romero JA, Kuczler FJ Jr. Isoniazid overdose: recognition and management. Am Fam Physician 1998;57(4):749-52. PMID 9490997
205: Rose DP. The interactions between vitamin B6 and hormones. Vitam Horm 1978;36:53-99. PMID 217175
206: Rosenberg IH. A history of the isolation and identification of vitamin B6. Ann Nutri Metab 2012;61:236-8. PMID 23183295
207: Ross RR. Use of pyridoxine hydrochloride to prevent isoniazid toxicity. J Am Med Assoc 1958;168:273-5. PMID 13575154
208: Rubinos C, Bruzzone MJ, Blodgett C, et al. Association of serum pyridoxal phosphate levels with established status epilepticus. Neurocrit Care 2023;38(1):41-51. PMID 36071331
209: Sadilkova K, Gospe SM Jr, Hahn SH. Simultaneous determination of alpha-aminoadipic semialdehyde, piperideine-6-carboxylate and pipecolic acid by LC-MS/MS for pyridoxine-dependent seizures and folinic acid-responsive seizures. J Neurosci Methods 2009;184(1):136-41. PMID 19631689
210: Sahakian V, Rouse D, Sipes S, Rose N, Niebyl J. Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. Obstet Gynecol 1991;78(1):33-6. PMID 2047064
211: Said ZM, Subramanian VS, Vaziri ND, Said HM. Pyridoxine uptake by colonocytes: a specific and regulated carrier-mediated process. Am J Physiol Cell Physiol 2008;294(5):C1192-7. PMID 18353902
212: Salam RA, Zuberi NF, Bhutta ZA. Pyridoxine (vitamin B6) supplementation during pregnancy or labour for maternal and neonatal outcomes. Cochrane Database Syst Rev 2015 Jun 3;(6):CD000179. PMID 26039815
213: Salkind AR, Hewitt CC. Coma from long-term overingestion of isoniazid. Arch Intern Med 1997;157(21):2518-20. PMID 9385305
214: Salomons GS, Bok LA, Struys EA, et al. An intriguing "silent" mutation and a founder effect in antiquitin (ALDH7A1). Ann Neurol 2007;62(4):414-8. PMID 17721876
215: Santoro L, Ragno M, Nucciotti R, Barbieri F, Caruso G. Pyridoxine neuropathy. A four-year electrophysiological and clinical follow-up of a severe case. Acta Neurol (Napoli) 1991;13:13-8. PMID 1867126
216: Santucci KA, Shah BR, Linakis JG. Acute isoniazid exposures and antidote availability. Pediatr Emerg Care 1999;15(2):99-101. PMID 10220077
217: Sawhney A, Singhal S, Patel R. Isolated pyridoxine deficiency presenting as peripheral neuropathy post-chemotherapy. Cureus 2022;14(7):e26725. PMID 35967133
218: Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, Brown MJ. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983;309(8):445-8. PMID 6308447
219: Schmitt B, Baumgartner M, Mills PB, et al. Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol 2010;52(7):e133-42. PMID 20370816
220: Scott K, Zeris S, Kothari MJ. Elevated B6 levels and peripheral neuropathies. Electromyogr Clin Neurophysiol 2008;48(5):219-23. PMID 18754531
221: Shah BR, Santucci K, Sinert R, Steiner P. Acute isoniazid neurotoxicity in an urban hospital. Pediatrics 1995;95(5):700-4. PMID 7724306
222: Sharp RA, Lowe JG, Johnston RN. Anti-tuberculous drugs and sideroblastic anaemia. Br J Clin Pract 1990;44(12):706-7. PMID 2102203
223: Sheehan P. Hyperemesis gravidarum--assessment and management. Aust Fam Physician 2007;36(9):698-701. PMID 17885701
224: Shiraku H, Nakashima M, Takeshita S, et al. PLPBP mutations cause variable phenotypes of developmental and epileptic encephalopathy. Epilepsia Open 2018;3(4):495-502. PMID 30525118
225: Siefkin AD, Albertson TE, Corbett MG. Isoniazid overdose: pharmacokinetics and effects of oral charcoal in treatment. Hum Toxicol 1987;6(6):497-501. PMID 3692494
226: Sievers ML, Herrier RN. Treatment of acute isoniazid toxicity. Am J Hosp Pharm 1975;32:202-6. PMID 1136966
227: Sievers ML, Cynamon MH, Bittker TE. Intentional isoniazid overdosage among southwestern American Indians. Am J Psychiatry 1975;132:662-5. PMID 1124816
228: Siskind MS, Thienemann D, Kirlin L. Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature. Nephron 1993;64:303-6. PMID 8321366
229: Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61(4):191-6. PMID 6269259
230: Sonkusare S. Hyperemesis gravidarum: a review. Med J Malaysia 2008;63(3):272-6. PMID 19248711
231: Sood AK, Dua A, Mahajan A. Management of isoniazid poisoning--case report. Indian J Med Sci 1996;50(7):247-9. PMID 8979544
232: Sousou JM, Griffith EM, Marsalisi C, Reddy P. Pyridoxine deficiency and neurologic dysfunction: an unlikely association. Cureus 2023;15(10):e47647. PMID 38021490
233: Standal BR, Kao-Chen SM, Yang GY, Char DF. Early changes in pyridoxine status of patients receiving isoniazid therapy. Am J Clin Nutr 1974;27(5):479-84. PMID 4274683
234: Stapley PJ, Ting LH, Hulliger M, Macpherson JM. Automatic postural responses are delayed by pyridoxine-induced somatosensory loss. J Neurosci 2002;22(14):5803-7. PMID 12122040
235: Sterman AB, Schaumburg HH, Asbury AK. The acute sensory neuronopathy syndrome: a distinct clinical entity. Ann Neurol 1980;7(4):354-8. PMID 6246836
236: Stewart SL, Thomas S, Höke E, Simpson D, Singleton JR, Höke A. Vitamin B6 levels do not correlate with severity of neuropathy in chronic idiopathic axonal polyneuropathy. J Peripher Nerv Syst 2022;27(1):31-7. PMID 34931740
237: Stockler S, Plecko B, Gospe SM Jr, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011;104(1-2):48-60. PMID 21704546
238: Stolwijk NN, Brands MM, Smit LS, van der Wel V, Hollak CEM, van Karnebeek CD. A vitamin a day keeps the doctor away: the need for high quality pyridoxal-5'-phosphate. Eur J Paediatr Neurol 2022;39:25-9. PMID 35636100
239: Striano P, Battaglia S, Giordano L, et al. Two novel ALDH7A1 (antiquitin) splicing mutations associated with pyridoxine-dependent seizures. Epilepsia 2009;50(4):933-6. PMID 18717709
240: Struys EA, Nota B, Bakkali A, Al Shahwan S, Salomons GS, Tabarki B. Pyridoxine-dependent epilepsy with elevated urinary α-amino adipic semialdehyde in molybdenum cofactor deficiency. Pediatrics 2012a;130(6):e1716-9. PMID 23147983
241: Struys EA, Bok LA, Emal D, Houterman S, Willemsen MA, Jakobs C. The measurement of urinary Δ¹-piperideine-6-carboxylate, the alter ego of α-aminoadipic semialdehyde, in Antiquitin deficiency. J Inherit Metab Dis 2012b;35(5):909-16. PMID 22249334
242: Sullivan EA, Geoffroy P, Weisman R, Hoffman R, Frieden TR. Isoniazid poisonings in New York City. J Emerg Med 1998;16:57-9. PMID 9472761
243: Szefler B, Czeleń P, Krawczyk P. The affinity of carboplatin to B-vitamins and nucleobases. Int J Mol Sci 2021;22(7):3634. PMID 33807309
244: Tai DY, Yeo JK, Eng PC, Wang YT. Intentional overdosage with isoniazid: case report and review of literature. Singapore Med J 1996;37(2):222-5. PMID 8942271
245: Tai WP, Yue H, Hu PJ. Coma caused by isoniazid poisoning in a patient treated with pyridoxine and hemodialysis. Adv Ther 2008;25(10):1085-8. PMID 18807228
246: Tajender V, Saluja J. INH induced status epilepticus: response to pyridoxine. Indian J Chest Dis Allied Sci 2006;48(3):205-6. PMID 18610679
247: Temmerman W, Dhondt A, Vandewoude K. Acute isoniazid intoxication: seizures, acidosis and coma. Acta Clin Belg 1999;54(4):211-6. PMID 10544512
248: Testai FD, Gorelick PB. Inherited metabolic disorders and stroke part 2: homocystinuria, organic acidurias, and urea cycle disorders. Arch Neurol 2010;67(2):148-53. PMID 20142522
249: Thompson MD, Killoran A, Percy ME, Nezarati M, Cole DEC, Hwang PA. Hyperphosphatasia with neurologic deficit: a pyridoxine-responsive seizure disorder? Pediat Neurol 2006;34(4):303-7. PMID 16638507
250: Tong Y. Seizures caused by pyridoxine (vitamin B6) deficiency in adults: a case report and literature review. Intractable Rare Dis Res 2014;3(2):52-6 PMID 25343127
251: Topcu I, Yentur EA, Kefi A, Ekici NZ, Sakarya M. Seizures, metabolic acidosis and coma resulting from acute isoniazid intoxication. Anaesth Intensive Care 2005;33:518-20. PMID 16119496
252: Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid-responsive neonatal seizures. J Child Neurol 1999;14(8):529-32. PMID 10456764
253: Tso WW, Kwong AK, Fung CW, Wong VC. Folinic acid responsive epilepsy in Ohtahara syndrome caused by STXBP1 mutation. Pediatr Neurol 2014;50(2):177-80. PMID 24315539
254: Tuberculosis Chemotherapy Centre. The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis: 1. An assessment of two vitamin B preparations and glutamic acid. Bull World Health Organ 1963;28(4):455-75. PMID 20604148
255: van der Watt JJ, Harrison TB, Benatar M, Heckmann JM. Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. Int J Tuberc Lung Dis 2011;15(6):722-8. PMID 21477422
256: van Karnebeek CD, Stockler-Ipsiroglu S, Jaggumantri S, et al. Lysine-restricted diet as adjunct therapy for pyridoxine-dependent epilepsy: the PDE Consortium Consensus Recommendations. JIMD Rep 2014;15:1-11. PMID 24748525
257: Veitch RL, Lumeng L, Li TK. Vitamin B6 metabolism in chronic alcohol abuse. The effect of ethanol oxidation on hepatic pyridoxal 5'-phosphate metabolism. J Clin Invest 1975;55(5):1026-32. PMID 1168205
258: Visser ME, Texeira-Swiegelaar C, Maartens G. The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2004;8(2):260-2. PMID 15139457
259: Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1995;173(3 Pt 1):881-4. PMID 7573262
260: Ware TL, Earl J, Salomons GS, et al. Typical and atypical phenotypes of PNPO deficiency with elevated CSF and plasma pyridoxamine on treatment. Dev Med Child Neurol 2014;56(5):498-502. PMID 24266778
261: Wason S, Lacouture PG, Lovejoy FH Jr. Single high-dose pyridoxine treatment for isoniazid overdose. JAMA 1981;246(10):1102-4. PMID 7265398
262: Watkins RC, Hambrick EL, Benjamin G, Chavda SN. Isoniazid toxicity presenting as seizures and metabolic acidosis. J Natl Med Assoc 1990;82(1):57, 62, 64. PMID 2304098
263: Webb JL. Nutritional effects of oral contraceptive use: a review. J Reprod Med 1980;25(4):150-6. PMID 7001015
264: Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 2012;366(10):904-13. PMID 22397652
265: Whyte MP, Leung E, Wilcox WR, et al. Natural history of perinatal and infantile hypophosphatasia: a retrospective study. J Pediatr 2019;209:116-24. PMID 30979546
266: Whyte MP, May JD, McAlister WH, et al. Vitamin B6 deficiency with normal plasma levels of pyridoxal 5'-phosphate in perinatal hypophosphatasia. Bone 2021;150:116007. PMID 34000433
267: Whyte MP, Zhang F, Wenkert D, et al. Hypophosphatasia: vitamin B6 status of affected children and adults. Bone 2022;154:116204. PMID 34547524
268: Wise A, Lemus HN, Fields M, Swan M, Bressman S. Refractory seizures secondary to vitamin B6 deficiency in Parkinson disease: the role of carbidopa-levodopa. Case Rep Neurol 2022;14(2):291-5. PMID 35949204
269: Woods E, Dawson C, Senthil L, Geberhiwot T. Cerebral venous thrombosis as the first presentation of classical homocystinuria in an adult patient. BMJ Case Rep 2017;2017:pii: bcr2016217477. PMID 28137899
270: Woolf K, Manore MM. Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis. J Am Diet Assoc 2008;108(3):443-53. PMID 18313425
271: Xu Y, Sladky JT, Brown MJ. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology 1989;39(8):1077-83. PMID 2761702
272: Yan J, Wu J, Xu M, Wang M, Guo W. Disrupted de novo pyrimidine biosynthesis impairs adult hippocampal neurogenesis and cognition in pyridoxine-dependent epilepsy. Sci Adv 2024;10(14):eadl2764. PMID 38579001
273: Yarbrough BE, Wood JP. Isoniazid overdose treated with high-dose pyridoxine. Ann Emerg Med 1983;12(5):303-5. PMID 6625281
274: Yasuda H, Hatano T, Honda T, et al. Vitamin B6 deficiency anemia attributed to levodopa/carbidopa intestinal gel therapy for Parkinson's disease: a diagnostic pitfall for myelodysplastic syndrome with ring sideroblasts. Intern Med 2022;61(24):3719-22. PMID 35569990
275: Yun S, Kim W, Kang MS, et al. Neuropathological changes in dorsal root ganglia induced by pyridoxine in dogs. BMC Neurosci 2020;21(1):11. PMID 32204694
276: Zhang Q, Qin Z, Yi S, Wei H, Zhou XZ, Shen F. Case report: variations in the ALPL gene in Chinese patients with hypophosphatasia. Front Genet 2021;12:732621. PMID 34712267
277: Zilber LA, Bajdakova ZL, Gardasjan AN, Konovalov NV, Bunina TL, Barabadze EM. The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis. 2. An assessment of the prophylactic effect of pyridoxine in low dosage. Bull World Health Organ 1963;29:457-81. PMID 14099673

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Douglas J Lanska MD MS MSPH

Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile

Former Authors

Jasvinder Chawla MD MBA

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: heredity may be a factor
Population groups selectively affected: None selectively affected
Occupation groups selectively affected: None selectively affected

ICD & OMIM codes

ICD-10: Pyridoxine deficiency: E53.1
ICD-11: Vitamin B6 deficiency: 5B5D

Acquired pyridoxine deficiency anaemia: 3A03.40

Other specified genetic epileptic syndromes with neonatal onset: 8A61.0Y

Disorders of pyridoxine metabolism: 5C59.2
OMIM: Autosomal recessive infantile hypophosphatasia: # 241500

Autosomal recessive pyridoxine-dependent neonatal epilepsy: # 266100

Autosomal recessive pyridoxine-responsive homocystinuria due to cystathionine beta-synthase deficiency: # 236200

Glycosylphosphatidylinositol biosynthesis defect 2: # 239300

Glycosylphosphatidylinositol biosynthesis defect 18: # 618143

Hyper-beta-alaninemia associated with Cohen syndrome: # 216550

Hyperprolinemia type II: # 239510

Pyridoxal phosphate-binding protein (PLPBP) deficiency: * 604436

Pyridoxamine 5'-phosphate oxidase (PNPO) deficiency: # 610090

Pyridoxine-dependent epilepsy: # 266100

X-linked and autosomal recessive forms of pyridoxine-responsive sideroblastic anemia: # 300751 and # 206000

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Pyridoxine deficiency and toxicity

Associated Disorders

Vitamin deficiency and toxicity

Differential Diagnosis

anemia
beriberi
depression
diabetic ketoacidosis
folic acid deficiency
- homocystinuria
- homocystinemia
- isoniazid toxicity
- neonatal seizures
- pellagra
- porphyria, acute intermittent
- other nutritional and metabolic sensory motor axonal neuropathies
- viral infections
- paraneoplastic conditions (paraneoplastic subacute sensory neuronopathy)
- dysimmune disorders (Sjögren syndrome, Miller Fisher syndrome, and Bickerstaff brainstem encephalitis)
- other inborn errors of metabolism (eg, mitochondrial encephalopathy, glycine encephalopathy)

Pyridoxine deficiency and toxicity …

Pyridoxine deficiency and toxicity

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Table 1. Biomarkers of Treatable Inborn Errors of Metabolism with Pyridoxine-Responsive Epilepsy

Management

Table 2. Pyridoxine Dosing Based on Underlying Indications

Special considerations

Pregnancy

Media

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

Brain death/death by neurologic criteria

Outpatient rehabilitation of chronic neurologic conditions

Pyridoxine deficiency and toxicity

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Table 1. Biomarkers of Treatable Inborn Errors of Metabolism with Pyridoxine-Responsive Epilepsy

Management

Table 2. Pyridoxine Dosing Based on Underlying Indications

Special considerations

Pregnancy

Media

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

Brain death/death by neurologic criteria

Outpatient rehabilitation of chronic neurologic conditions

This is an article preview.
Start a Free Account
to access the full version.